5-FU$DB00544$drug$Eloxatin$DB00526$true$mechanism$brand$Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. | 
Abilify$DB01238$brand$ALCOHOL$DB00898$true$advise$drug$Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.| 
ACETAMINOPHEN$DB00316$drug$ALCOHOL$DB00898$true$effect$drug$Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| 
ACETAMINOPHEN$DB00316$drug$Busulfex$DB01008$true$mechanism$brand$Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.| 
ACETAMINOPHEN$DB00316$drug$CAFFEINE$DB00201$true$effect$drug$Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.| Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.| 
ACETAMINOPHEN$DB00316$drug$CHLORDIAZEPOXIDE$DB00475$true$effect$drug$Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| 
ACETAMINOPHEN$DB00316$drug$Gleevec$DB00619$true$mechanism$brand$Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.| 
ACETAMINOPHEN$DB00316$drug$ISONIAZID$DB00951$true$effect$drug$Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.| 
ACETAMINOPHEN$DB00316$drug$THEOPHYLLINE$DB00277$true$effect$drug$Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | 
ACETAMINOPHEN$DB00316$drug$THEOPHYLLINE$DB00277$true$mechanism$drug$Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | 
ACETAZOLAMIDE$DB00819$drug$CYCLOSPORINE$DB00091$true$mechanism$drug$Acetazolamide may elevate cyclosporine levels.| 
ACETAZOLAMIDE$DB00819$drug$LITHIUM CATION$DB01356$true$mechanism$drug$Acetazolamide increases lithium excretion and the lithium may be decreased.| 
ACETAZOLAMIDE$DB00819$drug$LITHIUM$DB01356$true$mechanism$drug$Acetazolamide increases lithium excretion and the lithium may be decreased.| 
ACETAZOLAMIDE$DB00819$drug$QUINIDINE$DB00908$true$mechanism$drug$Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.| 
ACETAZOLAMIDE$DB00819$drug$SODIUM BICARBONATE$DB01390$true$effect$drug$Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.| 
ACETYLCHOLINE CHLORIDE$DB03128$drug$Suprofen$DB00870$true$effect$drug$Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| 
acetyl-L-carnitine$DB08842$drug$alpha-Lipoic acid$DB00166$true$effect$drug$(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.| 
ACITRETIN$DB00459$drug$ALCOHOL$DB00898$true$mechanism$drug$Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.| 
ACITRETIN$DB00459$drug$Glibenclamide$DB01016$true$effect$drug$Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.| 
ACITRETIN$DB00459$drug$PHENYTOIN$DB00252$true$mechanism$drug$Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.| 
ACTH$DB01285$group$AMPHOTERICIN B$DB00681$true$effect$drug$Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.| 
ADENOSINE PHOSPHATE$DB00415$drug$ALLOPURINOL$DB00437$true$effect$drug$It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.| Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| 
ADENOSINE$DB00640$drug$CAFFEINE$DB00201$true$effect$drug$The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.| 
ADENOSINE$DB00640$drug$CARBAMAZEPINE$DB00564$true$effect$drug$As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.| 
ADENOSINE$DB00640$drug$DIPYRIDAMOLE$DB00975$true$effect$drug$Adenosine effects are potentiated by dipyridamole.| Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.| 
ADENOSINE$DB00640$drug$THEOPHYLLINE$DB00277$true$effect$drug$The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.| 
ADL 8-2698$DB06274$drug$MORPHINE$DB00295$true$effect$drug$ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.&#x0D;| We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.| 
Adrenaline$DB00668$drug$Fluothane$DB01159$true$advise$brand$Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.| 
Aggrastat$DB00775$brand$ASPIRIN$DB00945$true$effect$brand$The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see| 
Akineton$DB00810$brand$MEPERIDINE$DB00454$true$effect$drug$Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.| 
Akineton$DB00810$brand$QUINIDINE$DB00908$true$effect$drug$Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.| 
ALCOHOL$DB00898$drug$ABACAVIR$DB01048$true$mechanism$drug$Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. | 
ALCOHOL$DB00898$drug$Abilify$DB01238$true$advise$brand$As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY| 
ALCOHOL$DB00898$drug$Antizol$DB01213$true$mechanism$brand$Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.| 
ALCOHOL$DB00898$drug$ASPIRIN$DB00945$true$effect$brand$Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.| 
ALCOHOL$DB00898$drug$Dilaudid$DB00327$true$effect$brand$Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.| 
ALCOHOL$DB00898$drug$DISULFIRAM$DB00822$true$effect$drug$Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. | 
ALCOHOL$DB00898$drug$HYDROCODONE$DB00956$true$effect$drug$Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.| 
ALCOHOL$DB00898$drug$Lexapro$DB01175$true$advise$brand$Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.| 
ALCOHOL$DB00898$drug$Methyprylon$DB01107$true$effect$drug$Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.| 
ALCOHOL$DB00898$drug$PENTAZOCINE, (-)-$DB00652$true$advise$drug$Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.| 
ALCOHOL$DB00898$drug$RIBOFLAVIN$DB00140$true$mechanism$drug$Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin| 
ALCOHOL$DB00898$drug$Sinequan$DB01142$true$mechanism$brand$Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.| 
ALCOHOL$DB00898$drug$TIAGABINE$DB00906$true$advise$drug$Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.| 
ALCOHOL$DB00898$drug$Vitamin B12$DB00115$true$mechanism$drug$Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| 
ALCOHOL$DB00898$drug$Wellbutrin$DB01156$true$advise$brand$Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.| The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| 
ALCOHOL$DB00898$drug$Wellbutrin$DB01156$true$effect$brand$Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.| The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| 
ALFENTANIL$DB00802$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
Alfentanyl$DB00802$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
Alfentanyl$DB00802$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
ALISKIREN$DB01258$drug$FUROSEMIDE$DB00695$true$mechanism$drug$Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.| 
Allegra$DB00950$brand$ALUMINUM$DB01370$true$advise$drug$ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.| 
Allegra$DB00950$brand$MAGNESIUM CATION$DB01378$true$advise$drug$ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.| 
Allegra$DB00950$brand$MAGNESIUM$DB01378$true$advise$drug$ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.| 
ALLOPURINOL$DB00437$drug$ADENOSINE PHOSPHATE$DB00415$true$effect$drug$The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| 
ALLOPURINOL$DB00437$drug$AMPICILLIN$DB00415$true$effect$drug$The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| 
ALLOPURINOL$DB00437$drug$AZATHIOPRINE$DB00993$true$advise$drug$In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| 
ALLOPURINOL$DB00437$drug$AZATHIOPRINE$DB00993$true$mechanism$drug$In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| 
ALLOPURINOL$DB00437$drug$CHLORPROPAMIDE$DB00672$true$effect$drug$The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| 
ALLOPURINOL$DB00437$drug$CHLORPROPAMIDE$DB00672$true$mechanism$drug$The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| 
ALLOPURINOL$DB00437$drug$DICUMAROL$DB00266$true$mechanism$drug$Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.| 
ALLOPURINOL$DB00437$drug$MERCAPTOPURINE$DB01033$true$advise$drug$In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| 
ALLOPURINOL$DB00437$drug$MERCAPTOPURINE$DB01033$true$mechanism$drug$In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| 
ALLOPURINOL$DB00437$drug$Videx$DB00900$true$mechanism$brand$Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).| 
ALMOTRIPTAN$DB00918$drug$Ketoconazole$DB01026$true$mechanism$drug$Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.| 
ALMOTRIPTAN$DB00918$drug$Verapamil$DB00661$true$mechanism$drug$Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.| 
ALOSETRON$DB00969$drug$CIMETIDINE$DB00501$true$advise$drug$Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.| 
ALOSETRON$DB00969$drug$CLARITHROMYCIN$DB01211$true$advise$drug$Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.| 
ALOSETRON$DB00969$drug$FLUVOXAMINE$DB00176$true$advise$drug$Concomitant administration of alosetron and fluvoxamine is contraindicated.| 
ALOSETRON$DB00969$drug$HYDRALAZINE$DB01275$true$effect$drug$Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| 
ALOSETRON$DB00969$drug$ISONIAZID$DB00951$true$effect$drug$Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| 
ALOSETRON$DB00969$drug$Ketoconazole$DB01026$true$advise$drug$Caution should be used when alosetron and ketoconazole are administered concomitantly.| 
ALOSETRON$DB00969$drug$PROCAINAMIDE$DB01035$true$effect$drug$Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.| 
ALOSETRON$DB00969$drug$TELITHROMYCIN$DB00976$true$advise$drug$Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.| 
ALOSETRON$DB00969$drug$VORICONAZOLE$DB00582$true$advise$drug$Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.| 
ALPRAZOLAM$DB00404$drug$ALCOHOL$DB00898$true$effect$drug$The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.| 
ALPRAZOLAM$DB00404$drug$AMIODARONE$DB01118$true$int$drug$Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| 
ALPRAZOLAM$DB00404$drug$APREPITANT$DB00673$true$advise$drug$The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| 
ALPRAZOLAM$DB00404$drug$CLARITHROMYCIN$DB01211$true$int$drug$Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| 
ALPRAZOLAM$DB00404$drug$CYCLOSPORINE$DB00091$true$int$drug$Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| 
ALPRAZOLAM$DB00404$drug$DIGOXIN$DB00390$true$mechanism$drug$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
ALPRAZOLAM$DB00404$drug$DILTIAZEM$DB00343$true$int$drug$Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| 
ALPRAZOLAM$DB00404$drug$ERGOTAMINE$DB00696$true$int$drug$Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| 
ALPRAZOLAM$DB00404$drug$ERYTHROMYCIN$DB00199$true$int$drug$Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| 
ALPRAZOLAM$DB00404$drug$FLUVOXAMINE$DB00176$true$advise$drug$This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| 
ALPRAZOLAM$DB00404$drug$FLUVOXAMINE$DB00176$true$effect$drug$This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| 
ALPRAZOLAM$DB00404$drug$FLUVOXAMINE$DB00176$true$mechanism$drug$This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.| Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| 
ALPRAZOLAM$DB00404$drug$ISONIAZID$DB00951$true$int$drug$Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.| 
ALPRAZOLAM$DB00404$drug$NIFEDIPINE$DB01115$true$int$drug$Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.| 
ALPRAZOLAM$DB00404$drug$PAROXETINE$DB00715$true$int$drug$Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| 
ALPRAZOLAM$DB00404$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
ALPRAZOLAM$DB00404$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
ALPRAZOLAM$DB00404$drug$SERTRALINE$DB01104$true$int$drug$Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.| 
ALUMINUM HYDROXIDE$DB06723$drug$ENOXACIN$DB00467$true$mechanism$drug$Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.| 
ALUMINUM HYDROXIDE$DB06723$drug$FOSINOPRIL$DB00492$true$mechanism$drug$Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.| 
ALUMINUM$DB01370$drug$Factive$DB01155$true$advise$brand$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| 
ALUMINUM$DB01370$drug$IBANDRONIC ACID$DB00710$true$mechanism$drug$Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| 
ALUMINUM$DB01370$drug$Skelid$DB01133$true$mechanism$brand$The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | 
ALUMINUM$DB01370$drug$Videx$DB00900$true$effect$brand$Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.| 
AMILORIDE$DB00594$drug$DOFETILIDE$DB00204$true$advise$drug$In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| 
AMINOSALICYLIC ACID$DB00233$drug$DIGOXIN$DB00390$true$mechanism$drug$Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.| 
AMINOSALICYLIC ACID$DB00233$drug$Lanoxin$DB00390$true$mechanism$brand$Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.| 
AMINOSALICYLIC ACID$DB00233$drug$Vitamin B12$DB00115$true$mechanism$drug$Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.| 
AMIODARONE$DB01118$drug$DIGOXIN$DB00390$true$mechanism$drug$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). | Amiodarone is known to raise serum digoxin levels. | 
AMIODARONE$DB01118$drug$INDINAVIR ANHYDROUS$DB00224$true$mechanism$drug$A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.| 
AMIODARONE$DB01118$drug$INDINAVIR$DB00224$true$mechanism$drug$A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.| 
AMIODARONE$DB01118$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
AMIODARONE$DB01118$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
AMIODARONE$DB01118$drug$Tikosyn$DB00204$true$advise$brand$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
AMITRIPTYLINE$DB00321$drug$CLONIDINE$DB00575$true$effect$drug$Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.| 
AMOXICILLIN ANHYDROUS$DB01060$drug$ALLOPURINOL$DB00437$true$effect$drug$Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| 
AMOXICILLIN$DB01060$drug$ALLOPURINOL$DB00437$true$effect$drug$Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| 
AMPHOTERICIN B$DB00681$drug$FLUCYTOSINE$DB01099$true$effect$drug$Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.| 
AMPHOTERICIN B$DB00681$drug$HYDROCORTISONE$DB00741$true$effect$drug$In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.| 
AMPHOTERICIN B$DB00681$drug$TUBOCURARINE$DB01199$true$effect$drug$Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).| 
Amphotericin$DB00681$drug$HIVID$DB00943$true$effect$drug$Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| 
Amphotericin$DB00681$drug$ZALCITABINE$DB00943$true$mechanism$drug$Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| 
AMPICILLIN$DB00415$drug$ALLOPURINOL$DB00437$true$effect$drug$Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.| 
AMPRENAVIR$DB00701$drug$RIFABUTIN$DB00615$true$effect$drug$Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. | Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. | Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. | 
AMPRENAVIR$DB00701$drug$RIFABUTIN$DB00615$true$mechanism$drug$Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. | Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. | Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. | 
AMPRENAVIR$DB00701$drug$RITONAVIR$DB00503$true$advise$drug$Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| 
AMPRENAVIR$DB00701$drug$RITONAVIR$DB00503$true$effect$drug$Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| 
Anafranil$DB01242$brand$DIGOXIN$DB00390$true$mechanism$drug$Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.| 
ANAGRELIDE$DB00261$drug$ASPIRIN$DB00945$true$effect$brand$Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.| 
ANAGRELIDE$DB00261$drug$THEOPHYLLINE$DB00277$true$mechanism$drug$Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.| 
ANASTROZOLE$DB01217$drug$TAMOXIFEN$DB00675$true$mechanism$drug$Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.| 
Antizol$DB01213$brand$ALCOHOL$DB00898$true$mechanism$drug$Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.| 
Antizol$DB01213$brand$CARBAMAZEPINE$DB00564$true$mechanism$drug$Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| 
Antizol$DB01213$brand$CIMETIDINE$DB00501$true$mechanism$drug$Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| 
Antizol$DB01213$brand$Ketoconazole$DB01026$true$mechanism$drug$Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| 
Antizol$DB01213$brand$PHENYTOIN$DB00252$true$mechanism$drug$Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| 
APOMORPHINE$DB00714$drug$ALOSETRON$DB00969$true$advise$drug$5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| 
APOMORPHINE$DB00714$drug$DOLASETRON$DB00757$true$advise$drug$5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| 
APOMORPHINE$DB00714$drug$GRANISETRON$DB00889$true$advise$drug$5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| 
APOMORPHINE$DB00714$drug$PALONOSETRON$DB00377$true$advise$drug$5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| 
APREPITANT$DB00673$drug$APREPITANT$DB00673$true$mechanism$drug$therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| 
APREPITANT$DB00673$drug$CLARITHROMYCIN$DB01211$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| 
APREPITANT$DB00673$drug$DEXAMETHASONE$DB01234$true$mechanism$drug$Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.| 
APREPITANT$DB00673$drug$DILTIAZEM$DB00343$true$mechanism$drug$Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.| 
APREPITANT$DB00673$drug$ETHINYL ESTRADIOL$DB00977$true$mechanism$drug$Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;| 
APREPITANT$DB00673$drug$Ketoconazole$DB01026$true$advise$drug$Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| 
APREPITANT$DB00673$drug$Ketoconazole$DB01026$true$mechanism$drug$Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| 
APREPITANT$DB00673$drug$METHYLPREDNISOLONE$DB00959$true$mechanism$drug$Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.| 
APREPITANT$DB00673$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.| Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.| 
APREPITANT$DB00673$drug$NEFAZODONE$DB01149$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| 
APREPITANT$DB00673$drug$NELFINAVIR$DB05251$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| 
APREPITANT$DB00673$drug$NORETHINDRONE$DB00717$true$mechanism$drug$Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;| 
APREPITANT$DB00673$drug$PAROXETINE$DB00715$true$mechanism$drug$Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.| 
APREPITANT$DB00673$drug$PHENYTOIN$DB00252$true$mechanism$drug$therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.| 
APREPITANT$DB00673$drug$RIFAMPIN$DB01045$true$mechanism$drug$Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.| therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| 
APREPITANT$DB00673$drug$RITONAVIR$DB00503$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| 
APREPITANT$DB00673$drug$TOLBUTAMIDE$DB01124$true$mechanism$drug$Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.| 
APREPITANT$DB00673$drug$TROLEANDOMYCIN$DB01361$true$advise$drug$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| 
Arava$DB01097$brand$METHOTREXATE$DB00563$true$effect$drug$In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.| 
Arava$DB01097$brand$RIFAMPIN$DB01045$true$advise$drug$Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.| Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.| 
Arava$DB01097$brand$RIFAMPIN$DB01045$true$mechanism$drug$Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.| Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.| 
ARIPIPRAZOLE$DB01238$drug$QUINIDINE$DB00908$true$mechanism$drug$Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.| 
ASPIRIN$DB00945$brand$Celebrex$DB00482$true$effect$brand$However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.| 
ASPIRIN$DB00945$brand$Disalcid$DB01399$true$effect$brand$ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. | 
ASPIRIN$DB00945$brand$Fenoprofen$DB00573$true$mechanism$drug$The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.| 
ASPIRIN$DB00945$brand$Flurbiprofen$DB00712$true$mechanism$drug$Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.| 
ASPIRIN$DB00945$brand$IBANDRONIC ACID$DB00710$true$advise$drug$However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.| 
ASPIRIN$DB00945$brand$INDOMETHACIN$DB00328$true$mechanism$drug$In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.| 
ASPIRIN$DB00945$brand$MELOXICAM$DB00814$true$mechanism$drug$Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. | 
ASPIRIN$DB00945$brand$METHAZOLAMIDE$DB00703$true$advise$drug$Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.| 
ASPIRIN$DB00945$brand$Mobic$DB00814$true$effect$brand$Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. | 
ASPIRIN$DB00945$brand$Nalfon$DB00573$true$mechanism$brand$Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.| 
ASPIRIN$DB00945$brand$Nicotinic Acid$DB00627$true$mechanism$drug$Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.| 
ASPIRIN$DB00945$brand$NIZATIDINE$DB00585$true$mechanism$drug$In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.| 
ASPIRIN$DB00945$brand$PHENYLBUTAZONE$DB00812$true$effect$drug$Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| 
ASPIRIN$DB00945$brand$PROBENECID$DB01032$true$effect$drug$Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| 
ASPIRIN$DB00945$brand$Retavase$DB00015$true$effect$brand$In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.| 
ASPIRIN$DB00945$brand$Skelid$DB01133$true$mechanism$brand$Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. | 
ASPIRIN$DB00945$brand$VALDECOXIB$DB00580$true$effect$drug$Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.| 
ASPIRIN$DB00945$brand$Vioxx$DB00533$true$effect$brand$Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.| 
ASPIRIN$DB00945$drug$Activase$DB00009$true$int$brand$In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.| 
ASPIRIN$DB00945$drug$TNKase$DB00031$true$effect$brand$Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. | 
ASTEMIZOLE$DB00637$drug$Ketoconazole$DB01026$true$advise$drug$Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| 
ASTEMIZOLE$DB00637$drug$Ketoconazole$DB01026$true$mechanism$drug$Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| 
ASTEMIZOLE$DB00637$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
ATORVASTATIN$DB01076$drug$ALISKIREN$DB01258$true$mechanism$drug$Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.| 
ATORVASTATIN$DB01076$drug$Crixivan$DB00224$true$advise$brand$Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.| 
ATORVASTATIN$DB01076$drug$DIGOXIN$DB00390$true$mechanism$drug$Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.| 
ATORVASTATIN$DB01076$drug$ERYTHROMYCIN$DB00199$true$mechanism$drug$Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.| 
ATORVASTATIN$DB01076$drug$ETHINYL ESTRADIOL$DB00977$true$mechanism$drug$Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.| Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.| 
ATORVASTATIN$DB01076$drug$NORETHINDRONE$DB00717$true$mechanism$drug$Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.| Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.| 
Atromid-S$DB00636$brand$PHENYTOIN$DB00252$true$mechanism$drug$Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.| 
Atromid-S$DB00636$brand$TOLBUTAMIDE$DB01124$true$mechanism$drug$Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.| 
Atropine$DB00572$drug$PRALIDOXIME$DB00733$true$advise$drug$The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.| When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. | When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| 
Atropine$DB00572$drug$PRALIDOXIME$DB00733$true$effect$drug$The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.| When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. | When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| 
Atropine$DB00572$drug$TRIPROLIDINE$DB00427$true$effect$drug$The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. | 
AURANOFIN$DB00995$drug$Cuprimine$DB00859$true$advise$brand$Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| 
AURANOFIN$DB00995$drug$Depen$DB00859$true$advise$brand$Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| 
AURANOFIN$DB00995$drug$PENICILLAMINE$DB00859$true$advise$drug$Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| 
Avonex$DB00060$brand$Tysabri$DB00108$true$mechanism$brand$After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.| 
AZATHIOPRINE$DB00993$drug$ALLOPURINOL$DB00437$true$advise$drug$Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.| Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.| 
AZATHIOPRINE$DB00993$drug$ALLOPURINOL$DB00437$true$mechanism$drug$Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.| Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.| 
AZLOCILLIN$DB01061$drug$AMIKACIN$DB00479$true$advise$drug$Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| 
AZLOCILLIN$DB01061$drug$CIPROFLOXACIN$DB00537$true$advise$drug$Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| 
AZLOCILLIN$DB01061$drug$NETILMICIN$DB00955$true$advise$drug$Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| 
AZLOCILLIN$DB01061$drug$TOBRAMYCIN$DB00684$true$advise$drug$Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.| 
BENTIROMIDE$DB00522$drug$ACETAMINOPHEN$DB00316$true$int$drug$Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| 
BENTIROMIDE$DB00522$drug$BENZOCAINE$DB01086$true$int$drug$Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| 
BENTIROMIDE$DB00522$drug$CHLORAMPHENICOL$DB00446$true$int$drug$Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| 
BENTIROMIDE$DB00522$drug$Chloromycetin$DB00446$true$int$brand$Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| 
BENTIROMIDE$DB00522$drug$LIDOCAINE$DB05291$true$int$drug$Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| 
BENTIROMIDE$DB00522$drug$PROCAINAMIDE$DB01035$true$int$drug$Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| 
BENTIROMIDE$DB00522$drug$Pronestyl$DB01035$true$int$brand$Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| 
BENTIROMIDE$DB00522$drug$Tylenol$DB00316$true$int$brand$Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).| 
BENZTHIAZIDE$DB00562$drug$ALCOHOL$DB00898$true$int$drug$Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| 
BENZTHIAZIDE$DB00562$drug$Aleve$DB00788$true$int$brand$Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| 
BENZTHIAZIDE$DB00562$drug$LITHIUM CATION$DB01356$true$int$drug$Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| 
BENZTHIAZIDE$DB00562$drug$LITHIUM$DB01356$true$int$drug$Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| 
BENZTHIAZIDE$DB00562$drug$NOREPINEPHRINE$DB00368$true$int$drug$Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.| 
Betagan$DB01210$brand$EPINEPHRINE$DB00668$true$effect$drug$Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.| 
Betaseron$DB00068$brand$ANTIPYRINE$DB01435$true$mechanism$drug$Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.| 
Bextra$DB00580$brand$LITHIUM CATION$DB01356$true$advise$drug$Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.| 
Bextra$DB00580$brand$LITHIUM$DB01356$true$advise$drug$Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.| 
BISMUTH SUBSALICYLATE$DB01294$drug$ENOXACIN$DB00467$true$mechanism$drug$Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.| 
BOSENTAN ANHYDROUS$DB00559$drug$ATORVASTATIN$DB01076$true$mechanism$drug$Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| 
BOSENTAN ANHYDROUS$DB00559$drug$GLYBURIDE$DB01016$true$mechanism$drug$Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.| 
BOSENTAN ANHYDROUS$DB00559$drug$Ketoconazole$DB01026$true$mechanism$drug$Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.| 
BOSENTAN ANHYDROUS$DB00559$drug$LOVASTATIN$DB00227$true$mechanism$drug$Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| 
BOSENTAN ANHYDROUS$DB00559$drug$SIMVASTATIN$DB00641$true$mechanism$drug$Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.| 
BOSENTAN$DB00559$drug$ATORVASTATIN$DB01076$true$mechanism$drug$Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| 
BOSENTAN$DB00559$drug$GLYBURIDE$DB01016$true$mechanism$drug$Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.| 
BOSENTAN$DB00559$drug$Ketoconazole$DB01026$true$mechanism$drug$Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.| 
BOSENTAN$DB00559$drug$LOVASTATIN$DB00227$true$mechanism$drug$Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| 
BOSENTAN$DB00559$drug$SIMVASTATIN$DB00641$true$mechanism$drug$Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.| 
Brevibloc$DB00187$brand$DIGOXIN$DB00390$true$advise$drug$Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| 
Brevibloc$DB00187$brand$DOPAMINE$DB00988$true$advise$drug$Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| 
Brevibloc$DB00187$brand$EPINEPHRINE$DB00668$true$advise$drug$Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| 
Brevibloc$DB00187$brand$MORPHINE$DB00295$true$advise$drug$Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.| 
Brevibloc$DB00187$brand$MORPHINE$DB00295$true$mechanism$drug$Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.| 
Brevibloc$DB00187$brand$NOREPINEPHRINE$DB00368$true$advise$drug$Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| 
Brevibloc$DB00187$brand$SUCCINYLCHOLINE$DB00202$true$advise$drug$Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| 
Brevibloc$DB00187$brand$Verapamil$DB00661$true$advise$drug$Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.| 
BUPRENORPHINE$DB00921$drug$Levo-Dromoran$DB00854$true$advise$brand$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| 
BUSPIRONE$DB00490$drug$DIGOXIN$DB00390$true$mechanism$drug$In vitro, buspirone may displace less firmly bound drugs like digoxin.| 
Busulfex$DB01008$brand$PHENYTOIN$DB00252$true$mechanism$drug$Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.| 
BUTALBITAL$DB00241$drug$ALCOHOL$DB00898$true$effect$drug$Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| 
BUTALBITAL$DB00241$drug$CHLORDIAZEPOXIDE$DB00475$true$effect$drug$Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| 
BUTORPHANOL$DB00611$drug$ALCOHOL$DB00898$true$effect$drug$Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.| 
BUTORPHANOL$DB00611$drug$ERYTHROMYCIN$DB00199$true$advise$drug$It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.| 
BUTORPHANOL$DB00611$drug$Levo-Dromoran$DB00854$true$advise$brand$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| 
CAFFEINE$DB00201$drug$ALCOHOL$DB00898$true$effect$drug$Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| 
CAFFEINE$DB00201$drug$CHLORDIAZEPOXIDE$DB00475$true$effect$drug$Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.| 
CAFFEINE$DB00201$drug$CIMETIDINE$DB00501$true$advise$drug$Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| 
CAFFEINE$DB00201$drug$CLOZAPINE$DB00363$true$mechanism$drug$Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| 
CAFFEINE$DB00201$drug$ENOXACIN$DB00467$true$effect$drug$Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.| Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.| 
CAFFEINE$DB00201$drug$ENOXACIN$DB00467$true$mechanism$drug$Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.| Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.| 
CAFFEINE$DB00201$drug$Ketoconazole$DB01026$true$advise$drug$Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| 
CAFFEINE$DB00201$drug$LEVOMEPROMAZINE$DB01403$true$effect$drug$Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. | 
CAFFEINE$DB00201$drug$Mexitil$DB00379$true$mechanism$brand$Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .| 
CAFFEINE$DB00201$drug$PHENOBARBITAL$DB01174$true$advise$drug$Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| 
CAFFEINE$DB00201$drug$PHENYTOIN$DB00252$true$advise$drug$Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| 
CALCIUM$DB01373$drug$ALENDRONIC ACID$DB00630$true$mechanism$drug$Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.| 
CALCIUM$DB01373$drug$Emcyt$DB01196$true$mechanism$brand$Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.| 
CALCIUM$DB01373$drug$IBANDRONIC ACID$DB00710$true$mechanism$drug$Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| 
CALCIUM$DB01373$drug$IRON$DB01592$true$mechanism$drug$However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. | 
Camptosar$DB00762$brand$DEXAMETHASONE$DB01234$true$effect$drug$Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.| 
Cancidas$DB00520$brand$CARBAMAZEPINE$DB00564$true$advise$drug$When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| 
Cancidas$DB00520$brand$CYCLOSPORINE$DB00091$true$effect$drug$There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.| 
Cancidas$DB00520$brand$DEXAMETHASONE$DB01234$true$advise$drug$When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| 
Cancidas$DB00520$brand$EFAVIRENZ$DB00625$true$advise$drug$When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| 
Cancidas$DB00520$brand$NEVIRAPINE$DB00238$true$advise$drug$When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| 
Cancidas$DB00520$brand$PHENYTOIN$DB00252$true$advise$drug$When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered| 
Cancidas$DB00520$brand$TACROLIMUS ANHYDROUS$DB00864$true$mechanism$drug$CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.| 
Cancidas$DB00520$brand$TACROLIMUS$DB00864$true$mechanism$drug$CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.| 
CARBACHOL$DB00411$drug$Suprofen$DB00870$true$effect$drug$Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| 
CARBAMAZEPINE$DB00564$drug$ARIPIPRAZOLE$DB01238$true$advise$drug$Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.| Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.| When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.| When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.| 
CARBAMAZEPINE$DB00564$drug$ARIPIPRAZOLE$DB01238$true$mechanism$drug$Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.| Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.| When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.| When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.| 
CARBAMAZEPINE$DB00564$drug$Cancidas$DB00520$true$mechanism$brand$In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| 
CARBAMAZEPINE$DB00564$drug$CLONAZEPAM$DB01068$true$mechanism$drug$Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| 
CARBAMAZEPINE$DB00564$drug$CLOZAPINE$DB00363$true$mechanism$drug$Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.| 
CARBAMAZEPINE$DB00564$drug$DOXYCYCLINE$DB00254$true$mechanism$drug$Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.| 
CARBAMAZEPINE$DB00564$drug$ESCITALOPRAM OXALATE$DB01175$true$mechanism$drug$Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.| 
CARBAMAZEPINE$DB00564$drug$ESCITALOPRAM$DB01175$true$mechanism$drug$Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.| 
CARBAMAZEPINE$DB00564$drug$ETHINYL ESTRADIOL$DB00977$true$mechanism$drug$Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| 
CARBAMAZEPINE$DB00564$drug$EXEMESTANE$DB00990$true$mechanism$drug$Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| 
CARBAMAZEPINE$DB00564$drug$FELBAMATE$DB00949$true$mechanism$drug$The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.| 
CARBAMAZEPINE$DB00564$drug$Felbatol$DB00949$true$mechanism$brand$Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.| 
CARBAMAZEPINE$DB00564$drug$ISONIAZID$DB00951$true$advise$drug$Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.| 
CARBAMAZEPINE$DB00564$drug$LAPATINIB DITOSYLATE$DB01259$true$mechanism$drug$Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.| 
CARBAMAZEPINE$DB00564$drug$LAPATINIB$DB01259$true$mechanism$drug$Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.| 
CARBAMAZEPINE$DB00564$drug$LITHIUM CATION$DB01356$true$effect$drug$Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.| 
CARBAMAZEPINE$DB00564$drug$LITHIUM$DB01356$true$effect$drug$Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.| 
CARBAMAZEPINE$DB00564$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. | 
CARBAMAZEPINE$DB00564$drug$MIFEPRISTONE$DB00834$true$mechanism$drug$John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). | 
CARBAMAZEPINE$DB00564$drug$Mivacron$DB01226$true$effect$brand$While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. | 
CARBAMAZEPINE$DB00564$drug$Nimbex$DB00565$true$effect$brand$While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.| 
CARBAMAZEPINE$DB00564$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
CARBAMAZEPINE$DB00564$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
CARBAMAZEPINE$DB00564$drug$Suprax$DB00671$true$mechanism$brand$Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.| 
Carboptic$DB00411$brand$Suprofen$DB00870$true$effect$drug$Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| 
CEFDINIR$DB00535$drug$IRON$DB01592$true$mechanism$drug$The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.| Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.| 
Celebrex$DB00482$brand$ASPIRIN$DB00945$true$advise$brand$Aspirin: CELEBREX can be used with low dose aspirin.| 
Celebrex$DB00482$brand$FLUCONAZOLE$DB00196$true$advise$drug$CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.| 
CELECOXIB$DB00482$drug$DOXORUBICIN$DB00997$true$effect$drug$We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. | 
CELECOXIB$DB00482$drug$FLUCONAZOLE$DB00196$true$int$drug$Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| 
CELECOXIB$DB00482$drug$FLUCONAZOLE$DB00196$true$mechanism$drug$Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| 
CELECOXIB$DB00482$drug$LITHIUM CATION$DB01356$true$int$drug$Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| 
CELECOXIB$DB00482$drug$LITHIUM$DB01356$true$int$drug$Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| 
CEPHALEXIN ANHYDROUS$DB00567$drug$METFORMIN$DB00331$true$advise$drug$Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| 
CEPHALEXIN ANHYDROUS$DB00567$drug$METFORMIN$DB00331$true$mechanism$drug$Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| 
CEPHALEXIN ANHYDROUS$DB00567$drug$PROBENECID$DB01032$true$mechanism$drug$Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| 
CEPHALEXIN$DB00567$drug$METFORMIN$DB00331$true$advise$drug$Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| 
CEPHALEXIN$DB00567$drug$METFORMIN$DB00331$true$mechanism$drug$Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| 
CEPHALEXIN$DB00567$drug$PROBENECID$DB01032$true$mechanism$drug$Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| 
Cerezyme$DB00053$brand$Zavesca$DB00419$true$advise$brand$Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.| 
CERIVASTATIN$DB00439$drug$ERYTHROMYCIN$DB00199$true$mechanism$drug$ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.| 
Cerubidine$DB00694$brand$DOXORUBICIN$DB00997$true$advise$drug$Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.| Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.| 
Cerubidine$DB00694$brand$DOXORUBICIN$DB00997$true$effect$drug$Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.| Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.| 
CHLORAMPHENICOL$DB00446$drug$CEFTAZIDIME$DB00438$true$effect$drug$Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.| 
CHLOROTRIANISENE$DB00269$drug$ASPIRIN$DB00945$true$int$brand$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$drug$BROMOCRIPTINE$DB01200$true$int$drug$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$drug$CALCIUM$DB01373$true$int$drug$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$drug$CYCLOSPORINE$DB00091$true$int$drug$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$drug$DANTROLENE$DB01219$true$int$drug$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$drug$NICOTINE$DB00184$true$int$drug$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$drug$Somatropin$DB00052$true$int$drug$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$drug$TAMOXIFEN$DB00675$true$int$drug$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLORPROMAZINE$DB00477$drug$AMITRIPTYLINE$DB00321$true$effect$drug$The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.| 
CHLORPROPAMIDE$DB00672$drug$ALLOPURINOL$DB00437$true$mechanism$drug$Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| 
CHLORPROPAMIDE$DB00672$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
CHLORPROTHIXENE$DB01239$drug$LITHIUM CATION$DB01356$true$mechanism$drug$Chlorprothixene may increase the plasma-level of concomitantly given lithium.| 
CHLORPROTHIXENE$DB01239$drug$LITHIUM$DB01356$true$mechanism$drug$Chlorprothixene may increase the plasma-level of concomitantly given lithium.| 
CHLORPROTHIXENE$DB01239$drug$Ultram$DB00193$true$advise$brand$Avoid the concomitant use of chlorprothixene and tramadol (Ultram).| 
CICLESONIDE$DB01410$drug$Ketoconazole$DB01026$true$mechanism$drug$In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.| 
CILOSTAZOL$DB01166$drug$ANAGRELIDE$DB00261$true$effect$drug$The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| 
CILOSTAZOL$DB01166$drug$DILTIAZEM$DB00343$true$mechanism$drug$Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..| 
CIMETIDINE$DB00501$drug$Alfenta$DB00802$true$mechanism$brand$Cimetidine reduces the clearance of ALFENTA.| 
CIMETIDINE$DB00501$drug$ALTRETAMINE$DB00488$true$mechanism$drug$Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.| 
CIMETIDINE$DB00501$drug$Cisapride$DB00604$true$mechanism$drug$The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.| H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.| 
CIMETIDINE$DB00501$drug$CLOZAPINE$DB00363$true$mechanism$drug$Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| 
CIMETIDINE$DB00501$drug$DILTIAZEM$DB00343$true$mechanism$drug$A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.| The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.| 
CIMETIDINE$DB00501$drug$DOFETILIDE$DB00204$true$mechanism$drug$Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).| 
CIMETIDINE$DB00501$drug$Ellence$DB00445$true$advise$brand$Cimetidine treatment should be stopped during treatment with ELLENCE.| 
CIMETIDINE$DB00501$drug$EPIRUBICIN$DB00445$true$mechanism$drug$Cimetidine increased the AUC of epirubicin by 50%.| 
CIMETIDINE$DB00501$drug$GABAPENTIN$DB00996$true$mechanism$drug$Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.| Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.| 
CIMETIDINE$DB00501$drug$Iressa$DB00317$true$mechanism$brand$Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.| 
CIMETIDINE$DB00501$drug$MEBENDAZOLE$DB00643$true$mechanism$drug$Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.| 
CIMETIDINE$DB00501$drug$Mexitil$DB00379$true$mechanism$brand$Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; | 
CIMETIDINE$DB00501$drug$NIFEDIPINE$DB01115$true$mechanism$drug$Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.| 
CIMETIDINE$DB00501$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). | Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
CIMETIDINE$DB00501$drug$ROFECOXIB$DB00533$true$mechanism$drug$Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.| 
CIMETIDINE$DB00501$drug$Tikosyn$DB00204$true$mechanism$brand$Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.| 
CIMETIDINE$DB00501$drug$TRIMETREXATE$DB01157$true$mechanism$drug$In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. | 
CIMETIDINE$DB00501$drug$Xanax$DB00404$true$advise$brand$Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).| 
CIMETIDINE$DB00501$drug$ZALCITABINE$DB00943$true$mechanism$drug$Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.| 
CIMETIDINE$DB00501$drug$ZALEPLON$DB00962$true$mechanism$drug$Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.| 
CINACALCET$DB01012$drug$AMITRIPTYLINE$DB00321$true$mechanism$drug$Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.| 
CINOXACIN$DB00827$drug$CAFFEINE$DB00201$true$advise$drug$Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.| 
CIPROFLOXACIN$DB00537$drug$ALUMINUM$DB01370$true$mechanism$drug$Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
CIPROFLOXACIN$DB00537$drug$CAFFEINE$DB00201$true$mechanism$drug$Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.| 
CIPROFLOXACIN$DB00537$drug$CALCIUM$DB01373$true$mechanism$drug$Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
CIPROFLOXACIN$DB00537$drug$CIPROFLOXACIN$DB00537$true$mechanism$drug$Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
CIPROFLOXACIN$DB00537$drug$CYCLOSPORINE$DB00091$true$effect$drug$Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.| 
CIPROFLOXACIN$DB00537$drug$DIDANOSINE$DB00900$true$mechanism$drug$In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.| The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.| 
CIPROFLOXACIN$DB00537$drug$GLYBURIDE$DB01016$true$effect$drug$Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.| 
CIPROFLOXACIN$DB00537$drug$IRON$DB01592$true$mechanism$drug$Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
CIPROFLOXACIN$DB00537$drug$MAGNESIUM CATION$DB01378$true$mechanism$drug$Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
CIPROFLOXACIN$DB00537$drug$MAGNESIUM$DB01378$true$mechanism$drug$Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
CIPROFLOXACIN$DB00537$drug$MORPHINE$DB00295$true$mechanism$drug$Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. | 
CIPROFLOXACIN$DB00537$drug$THEOPHYLLINE$DB00277$true$mechanism$drug$Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.| 
CIPROFLOXACIN$DB00537$drug$Videx$DB00900$true$mechanism$brand$Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.| 
CIPROFLOXACIN$DB00537$drug$ZINC$DB01593$true$mechanism$drug$Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
Cisapride$DB00604$drug$ERYTHROMYCIN$DB00199$true$mechanism$drug$There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| 
Cisapride$DB00604$drug$Ketoconazole$DB01026$true$effect$drug$A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| 
Cisapride$DB00604$drug$Ketoconazole$DB01026$true$mechanism$drug$A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| 
Cisapride$DB00604$drug$PROCAINAMIDE$DB01035$true$advise$drug$Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);| 
Cisapride$DB00604$drug$QUINIDINE$DB00908$true$advise$drug$Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);| 
Cisapride$DB00604$drug$Sotalol$DB00489$true$advise$drug$Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);| 
Cisapride$DB00604$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
CLARITHROMYCIN$DB01211$drug$Cisapride$DB00604$true$mechanism$drug$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
CLARITHROMYCIN$DB01211$drug$DIGOXIN$DB00390$true$mechanism$drug$Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| 
CLARITHROMYCIN$DB01211$drug$NEVIRAPINE$DB00238$true$mechanism$drug$Clarithromycin exposure was significantly decreased by nevirapine;| 
CLARITHROMYCIN$DB01211$drug$PIMOZIDE$DB01100$true$advise$drug$Concomitant administration of clarithromycin with pimozide is contraindicated.| 
CLARITHROMYCIN$DB01211$drug$SIMVASTATIN$DB00641$true$mechanism$drug$DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. | 
CLINDAMYCIN$DB01190$drug$ERYTHROMYCIN$DB00199$true$effect$drug$Antagonism has been demonstrated between clindamycin and erythromycin in vitro.| 
CLONAZEPAM$DB01068$drug$PROPANTHELINE$DB00782$true$mechanism$drug$In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.| 
CLONIDINE$DB00575$drug$ALCOHOL$DB00898$true$effect$drug$Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.| 
CLOPIDOGREL$DB00758$drug$ESOMEPRAZOLE$DB00736$true$advise$drug$Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. | 
CLOTRIMAZOLE$DB00257$drug$TRIMETREXATE$DB01157$true$mechanism$drug$Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. | 
CLOZAPINE$DB00363$drug$ALCOHOL$DB00898$true$effect$drug$Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.| 
CLOZAPINE$DB00363$drug$Atropine$DB00572$true$effect$drug$Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.| 
CLOZAPINE$DB00363$drug$CARBAMAZEPINE$DB00564$true$advise$drug$Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.| 
CLOZAPINE$DB00363$drug$Encainide$DB01228$true$advise$drug$Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| 
CLOZAPINE$DB00363$drug$FLUVOXAMINE$DB00176$true$advise$drug$Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.| 
CLOZAPINE$DB00363$drug$PAROXETINE$DB00715$true$mechanism$drug$However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| 
CLOZAPINE$DB00363$drug$QUINIDINE$DB00908$true$advise$drug$Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| 
CLOZAPINE$DB00363$drug$SERTRALINE$DB01104$true$mechanism$drug$However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| 
COCAINE$DB00907$drug$DIACETYLMORPHINE$DB01452$true$effect$drug_n$Cocaine sometimes proves to be fatal when used in combination with heroin.| 
COCAINE$DB00907$drug$NOREPINEPHRINE$DB00368$true$effect$drug$The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p &lt; 0.05) but not in functional class IV myocardium. | 
CODEINE$DB00318$drug$ALCOHOL$DB00898$true$effect$drug$The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.| Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.| 
COLCHICINE$DB01394$drug$Vitamin B12$DB00115$true$mechanism$drug$Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| 
Copegus$DB00811$brand$DIDANOSINE$DB00900$true$advise$drug$Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.| 
Coreg$DB01136$brand$DILTIAZEM$DB00343$true$advise$drug$As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.| Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.| 
Coreg$DB01136$brand$DILTIAZEM$DB00343$true$effect$drug$As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.| Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.| 
Coreg$DB01136$brand$Verapamil$DB00661$true$advise$drug$As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.| 
Crixivan$DB00224$brand$ATAZANAVIR$DB01072$true$advise$drug$Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.| 
Crixivan$DB00224$brand$DELAVIRDINE$DB00705$true$advise$drug$Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.| 
Crixivan$DB00224$brand$INDINAVIR ANHYDROUS$DB00224$true$effect$drug$CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.| 
Crixivan$DB00224$brand$INDINAVIR$DB00224$true$effect$drug$CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.| 
Cyclophosphamide$DB00531$drug$ALLOPURINOL$DB00437$true$effect$drug$Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.| 
Cyclophosphamide$DB00531$drug$Cerubidine$DB00694$true$effect$brand$Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.| 
Cyclophosphamide$DB00531$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.| 
Cyclosporin A$DB00091$drug$ETOPOSIDE$DB00773$true$mechanism$drug$High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.| 
CYCLOSPORINE$DB00091$drug$DILTIAZEM$DB00343$true$advise$drug$In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.| If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.| 
CYCLOSPORINE$DB00091$drug$DILTIAZEM$DB00343$true$mechanism$drug$In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.| If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.| 
CYCLOSPORINE$DB00091$drug$NORFLOXACIN$DB01059$true$mechanism$drug$Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.| 
CYCLOSPORINE$DB00091$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
CYCLOSPORINE$DB00091$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
CYCLOSPORINE$DB00091$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
Cytadren$DB00357$brand$DEXAMETHASONE$DB01234$true$mechanism$drug$Cytadren accelerates the metabolism of dexamethasone;| 
Cytosine arabinoside$DB00987$drug$FLUCYTOSINE$DB01099$true$effect$drug$Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.| 
d-amphetamine$DB01576$drug$DESIPRAMINE$DB01151$true$mechanism$drug$d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| 
d-amphetamine$DB01576$drug$PROTRIPTYLINE$DB00344$true$mechanism$drug$d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| 
DANAZOL$DB01406$drug$LOVASTATIN$DB00227$true$effect$drug$Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).| 
DANTROLENE$DB01219$drug$VECURONIUM$DB01339$true$effect$drug$Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.| 
DAPSONE$DB00250$drug$CLOFAZIMINE$DB00845$true$advise$drug$If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.| 
DAPSONE$DB00250$drug$Lamprene$DB00845$true$effect$brand$Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.| 
DAPSONE$DB00250$drug$PYRIMETHAMINE$DB00205$true$effect$drug$With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions| 
DAPSONE$DB00250$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
DAPSONE$DB00250$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
DASATINIB ANHYDROUS$DB01254$drug$PACLITAXEL$DB01229$true$effect$drug$Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); | HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. | Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. | The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.&#x0D;| Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.| 
DASATINIB$DB01254$drug$PACLITAXEL$DB01229$true$effect$drug$HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. | Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.| The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.&#x0D;| Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); | Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. | 
DECAMETHONIUM$DB01245$drug$Coly-Mycin M$DB01111$true$effect$brand$Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| 
DELAVIRDINE$DB00705$drug$Videx$DB00900$true$advise$brand$To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| 
DELAVIRDINE$DB00705$drug$Videx$DB00900$true$mechanism$brand$To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| 
Demser$DB00765$brand$ALCOHOL$DB00898$true$effect$drug$Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.| 
Demser$DB00765$brand$HALOPERIDOL$DB00502$true$advise$drug$Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. | 
DESIPRAMINE$DB01151$drug$ALPRAZOLAM$DB00404$true$mechanism$drug$The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.| 
DESIPRAMINE$DB01151$drug$CHLORDIAZEPOXIDE$DB00475$true$effect$drug$If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.| 
DESIPRAMINE$DB01151$drug$DIAZEPAM$DB00829$true$effect$drug$If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.| 
DESIPRAMINE$DB01151$drug$NOREPINEPHRINE$DB00368$true$effect$drug$The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p &lt; 0.05) but not in functional class IV myocardium. | 
DEXAMETHASONE$DB01234$drug$ALBENDAZOLE$DB00518$true$mechanism$drug$Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.| 
DEXAMETHASONE$DB01234$drug$APREPITANT$DB00673$true$advise$drug$The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.| 
DEXAMETHASONE$DB01234$drug$APREPITANT$DB00673$true$mechanism$drug$The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.| 
DEXAMETHASONE$DB01234$drug$Cancidas$DB00520$true$mechanism$brand$In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| 
DEXAMETHASONE$DB01234$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
DEXAMETHASONE$DB01234$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
DEXBROMPHENIRAMINE$DB00405$drug$ALCOHOL$DB00898$true$effect$drug$Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| 
DEXBROMPHENIRAMINE$DB00405$drug$ALCOHOL$DB00898$true$int$drug$Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| 
DEXMEDETOMIDINE$DB00633$drug$EPHEDRINE$DB01364$true$effect$drug$In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. | At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. | We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.| 
DEXTROMETHORPHAN$DB00514$drug$VALDECOXIB$DB00580$true$mechanism$drug$Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.| 
DEZOCINE$DB01209$drug$Levo-Dromoran$DB00854$true$advise$brand$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| 
DIACETYLMORPHINE$DB01452$drug_n$ALCOHOL$DB00898$true$effect$drug$Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.| 
DIACETYLMORPHINE$DB01452$drug_n$DIAZEPAM$DB00829$true$effect$drug$Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.| 
DIACETYLMORPHINE$DB01452$drug_n$Valium$DB00829$true$effect$brand$Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.| 
Diamox$DB00819$brand$PHENYTOIN$DB00252$true$mechanism$drug$DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.| 
Diamox$DB00819$brand$PRIMIDONE$DB00794$true$advise$drug$By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.| Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.| 
Diamox$DB00819$brand$PRIMIDONE$DB00794$true$mechanism$drug$By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.| Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.| 
DIAZEPAM$DB00829$drug$FLUVOXAMINE$DB00176$true$advise$drug$Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.| 
DIAZEPAM$DB00829$drug$INDOMETHACIN$DB00328$true$effect$drug$Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. | 
DIAZEPAM$DB00829$drug$MORPHINE$DB00295$true$effect$drug$Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. | 
DIAZEPAM$DB00829$drug$VALDECOXIB$DB00580$true$mechanism$drug$Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.| 
DIAZOXIDE$DB01119$drug$HYDRALAZINE$DB01275$true$effect$drug$Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.| 
DICLOFENAC$DB00586$drug$ASPIRIN$DB00945$true$advise$brand$Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| 
DICLOFENAC$DB00586$drug$ASPIRIN$DB00945$true$mechanism$brand$Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| 
DICLOFENAC$DB00586$drug$CYCLOSPORINE$DB00091$true$effect$drug$Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| 
DICLOFENAC$DB00586$drug$DIGOXIN$DB00390$true$effect$drug$Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| 
DICLOFENAC$DB00586$drug$DIGOXIN$DB00390$true$mechanism$drug$Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| 
DICLOFENAC$DB00586$drug$LITHIUM CATION$DB01356$true$effect$drug$Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.| In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| 
DICLOFENAC$DB00586$drug$LITHIUM CATION$DB01356$true$mechanism$drug$Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.| In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| 
DICLOFENAC$DB00586$drug$LITHIUM$DB01356$true$effect$drug$In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.| 
DICLOFENAC$DB00586$drug$LITHIUM$DB01356$true$mechanism$drug$In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.| 
DICLOFENAC$DB00586$drug$METHOTREXATE$DB00563$true$effect$drug$Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| 
DICLOFENAC$DB00586$drug$METHOTREXATE$DB00563$true$mechanism$drug$Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| 
DICLOFENAC$DB00586$drug$PREDNISOLONE$DB00860$true$mechanism$drug$Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| 
DICLOFENAC$DB00586$drug$SALICYLIC ACID$DB00936$true$mechanism$drug$Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| 
DICLOFENAC$DB00586$drug$TOLBUTAMIDE$DB01124$true$mechanism$drug$Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| 
DICYCLOMINE$DB00804$drug$Cisapride$DB00604$true$effect$drug$Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.| 
DIDANOSINE$DB00900$drug$Factive$DB01155$true$advise$brand$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| 
DIDANOSINE$DB00900$drug$NORFLOXACIN$DB01059$true$advise$drug$Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| 
Diflucan$DB00196$brand$CYCLOSPORINE$DB00091$true$advise$drug$Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. | Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. | 
Diflucan$DB00196$brand$CYCLOSPORINE$DB00091$true$mechanism$drug$Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. | Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. | 
Diflucan$DB00196$brand$GLIPIZIDE$DB01067$true$mechanism$drug$DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | 
Diflucan$DB00196$brand$GLYBURIDE$DB01016$true$effect$drug$one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. | DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | 
Diflucan$DB00196$brand$GLYBURIDE$DB01016$true$mechanism$drug$one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. | DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | 
Diflucan$DB00196$brand$PHENYTOIN$DB00252$true$advise$drug$Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. | Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. | 
Diflucan$DB00196$brand$PHENYTOIN$DB00252$true$mechanism$drug$Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. | Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. | 
Diflucan$DB00196$brand$RIFAMPIN$DB01045$true$advise$drug$Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin. | 
Diflucan$DB00196$brand$THEOPHYLLINE$DB00277$true$advise$drug$Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. | Theophylline: DIFLUCAN increases the serum concentrations of theophylline. | 
Diflucan$DB00196$brand$THEOPHYLLINE$DB00277$true$mechanism$drug$Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. | Theophylline: DIFLUCAN increases the serum concentrations of theophylline. | 
Diflucan$DB00196$brand$TOLBUTAMIDE$DB01124$true$mechanism$drug$DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. | 
DIFLUNISAL$DB00861$drug$ACETAMINOPHEN$DB00316$true$advise$drug$Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.| Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.| Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.| 
DIFLUNISAL$DB00861$drug$ACETAMINOPHEN$DB00316$true$effect$drug$Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.| Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.| Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.| 
DIFLUNISAL$DB00861$drug$ACETAMINOPHEN$DB00316$true$mechanism$drug$Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.| Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.| Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.| 
DIFLUNISAL$DB00861$drug$ASPIRIN$DB00945$true$mechanism$brand$Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.| 
DIFLUNISAL$DB00861$drug$FUROSEMIDE$DB00695$true$effect$drug$Diflunisal decreased the hyperuricemic effect of furosemide.| 
DIFLUNISAL$DB00861$drug$HYDROCHLOROTHIAZIDE$DB00999$true$effect$drug$Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.| Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.| 
DIFLUNISAL$DB00861$drug$HYDROCHLOROTHIAZIDE$DB00999$true$mechanism$drug$Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.| Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.| 
DIFLUNISAL$DB00861$drug$Indocin$DB00328$true$advise$brand$Therefore, diflunisal and INDOCIN should not be used concomitantly.| 
DIFLUNISAL$DB00861$drug$INDOMETHACIN$DB00328$true$mechanism$drug$Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.| In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.| 
DIFLUNISAL$DB00861$drug$METHOTREXATE$DB00563$true$advise$drug$Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.| 
DIFLUNISAL$DB00861$drug$NAPROXEN$DB00788$true$mechanism$drug$Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.| 
DIGOXIN$DB00390$drug$Adenocard$DB00640$true$effect$brand$Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| 
DIGOXIN$DB00390$drug$AMINOSALICYLIC ACID$DB00233$true$advise$drug$In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.| 
DIGOXIN$DB00390$drug$AMIODARONE$DB01118$true$mechanism$drug$These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.| 
DIGOXIN$DB00390$drug$Brevibloc$DB00187$true$mechanism$brand$When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.| 
DIGOXIN$DB00390$drug$CONIVAPTAN$DB00872$true$mechanism$drug$Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.| 
DIGOXIN$DB00390$drug$Coreg$DB01136$true$advise$brand$Both digoxin and COREG slow AV conduction.| Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.| 
DIGOXIN$DB00390$drug$Coreg$DB01136$true$effect$brand$Both digoxin and COREG slow AV conduction.| Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.| 
DIGOXIN$DB00390$drug$DIGOXIN$DB00390$true$mechanism$drug$Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.| 
DIGOXIN$DB00390$drug$DOFETILIDE$DB00204$true$effect$drug$In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.| 
DIGOXIN$DB00390$drug$Flolan$DB01240$true$mechanism$brand$However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.| In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| 
DIGOXIN$DB00390$drug$Ketoconazole$DB01026$true$advise$drug$It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.| 
DIGOXIN$DB00390$drug$METOCLOPRAMIDE$DB01233$true$mechanism$drug$Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). | 
DIGOXIN$DB00390$drug$NIFEDIPINE$DB01115$true$advise$drug$Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| 
DIGOXIN$DB00390$drug$NIFEDIPINE$DB01115$true$int$drug$Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.| 
DIGOXIN$DB00390$drug$PERINDOPRIL$DB00790$true$mechanism$drug$Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. | 
DIGOXIN$DB00390$drug$SITAGLIPTIN PHOSPHATE$DB01261$true$mechanism$drug$Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. | 
DIGOXIN$DB00390$drug$SITAGLIPTIN$DB01261$true$mechanism$drug$Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. | 
DIGOXIN$DB00390$drug$SULFASALAZINE$DB00795$true$mechanism$drug$Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. | 
DIGOXIN$DB00390$drug$Vaprisol$DB00872$true$mechanism$brand$Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.| 
DIHYDROERGOTAMINE$DB00320$drug$Axert$DB00918$true$advise$brand$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| 
DIHYDROERGOTAMINE$DB00320$drug$Frova$DB00998$true$advise$brand$Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| 
DIHYDROERGOTAMINE$DB00320$drug$NARATRIPTAN$DB00952$true$advise$drug$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| 
DIHYDROERGOTAMINE$DB00320$drug$ProAmatine$DB00211$true$effect$brand$The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | 
DIHYDROERGOTAMINE$DB00320$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
DIHYDROERGOTAMINE$DB00320$drug$SUMATRIPTAN SUCCINATE$DB00669$true$advise$drug$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | 
DIHYDROERGOTAMINE$DB00320$drug$SUMATRIPTAN$DB00669$true$advise$drug$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | 
DILTIAZEM$DB00343$drug$APREPITANT$DB00673$true$advise$drug$Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.| 
DILTIAZEM$DB00343$drug$CARBAMAZEPINE$DB00564$true$mechanism$drug$Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.| 
DILTIAZEM$DB00343$drug$CIMETIDINE$DB00501$true$advise$drug$Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.| 
DILTIAZEM$DB00343$drug$CYCLOSPORINE$DB00091$true$int$drug$A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.| 
DILTIAZEM$DB00343$drug$FENTANYL$DB00813$true$mechanism$drug$The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.| 
DILTIAZEM$DB00343$drug$LOVASTATIN$DB00227$true$mechanism$drug$In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;| 
DILTIAZEM$DB00343$drug$MIDAZOLAM$DB00683$true$effect$drug$Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| 
DILTIAZEM$DB00343$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| 
DILTIAZEM$DB00343$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
DILTIAZEM$DB00343$drug$RIFAMPIN$DB01045$true$advise$drug$Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.| 
DILTIAZEM$DB00343$drug$SIROLIMUS$DB00877$true$mechanism$drug$CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. | Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.&#x0D;| 
DILTIAZEM$DB00343$drug$Tikosyn$DB00204$true$advise$brand$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
DILTIAZEM$DB00343$drug$TRIAZOLAM$DB00897$true$effect$drug$These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| 
DILTIAZEM$DB00343$drug$TRIAZOLAM$DB00897$true$mechanism$drug$These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| 
DIMENHYDRINATE$DB00985$drug$APOMORPHINE$DB00714$true$effect$drug$Dimenhydrinate may decrease emetic response to apomorphine.| 
DIPHENIDOL$DB01231$drug$APOMORPHINE$DB00714$true$effect$drug$apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.| 
DIPHENOLIC ACID$DB00313$drug$PHENOBARBITAL$DB01174$true$effect$drug$Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | 
DIPHENOLIC ACID$DB00313$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | 
DIPHENOLIC ACID$DB00313$drug$TEMOZOLOMIDE$DB00853$true$mechanism$drug$Administration of valproic acid decreases oral clearance of temozolomide by about 5%. | 
DIPHENOXYLATE$DB01081$drug$DIGOXIN$DB00390$true$mechanism$drug$Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| 
Diprivan$DB00818$brand$FENTANYL$DB00813$true$effect$drug$The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | 
Diprivan$DB00818$brand$MEPERIDINE$DB00454$true$effect$drug$The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | 
Diprivan$DB00818$brand$MORPHINE$DB00295$true$effect$drug$The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) | 
DIPYRIDAMOLE$DB00975$drug$Activase$DB00009$true$effect$brand$In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.| 
DIPYRIDAMOLE$DB00975$drug$ADENOSINE$DB00640$true$mechanism$drug$Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.| 
DIPYRIDAMOLE$DB00975$drug$Retavase$DB00015$true$effect$brand$In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.| 
DIPYRIDAMOLE$DB00975$drug$TNKase$DB00031$true$effect$brand$Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. | 
DIPYRONE$DB04817$drug$ASPIRIN$DB00945$true$effect$drug$Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| 
DISULFIRAM$DB00822$drug$PHENYTOIN$DB00252$true$advise$drug$SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.| DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.| 
DISULFIRAM$DB00822$drug$PHENYTOIN$DB00252$true$effect$drug$SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.| DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.| 
Dobutamine$DB00841$drug$NITROPRUSSIDE$DB00325$true$effect$drug$Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.| 
Dobutamine$DB00841$drug$SODIUM BICARBONATE$DB01390$true$int$drug$norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. | 
DOCETAXEL$DB01248$drug$CYCLOSPORINE$DB00091$true$mechanism$drug$In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.| 
DOCETAXEL$DB01248$drug$ERYTHROMYCIN$DB00199$true$mechanism$drug$In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.| 
DOCETAXEL$DB01248$drug$Ketoconazole$DB01026$true$mechanism$drug$In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.| 
DOCETAXEL$DB01248$drug$SUNITINIB$DB01268$true$effect$drug$The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib. | Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.| When cells were exposed to docetaxel followed by sunitinib, synergism was observed. | 
DOCETAXEL$DB01248$drug$TROLEANDOMYCIN$DB01361$true$mechanism$drug$In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.| 
DOLASETRON$DB00757$drug$CIMETIDINE$DB00501$true$mechanism$drug$Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| 
DOLASETRON$DB00757$drug$RIFAMPIN$DB01045$true$mechanism$drug$Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| 
DOPAMINE$DB00988$drug$Bretylium tosylate$DB01158$true$effect$drug$The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.| 
Dostinex$DB00248$brand$METOCLOPRAMIDE$DB01233$true$advise$drug$DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.| 
DOXORUBICIN$DB00997$drug$Nexavar$DB00398$true$advise$brand$Caution is recommended when administering doxorubicin with NEXAVAR. | 
DOXORUBICIN$DB00997$drug$Proleukin$DB00041$true$effect$brand$Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.| 
DOXORUBICIN$DB00997$drug$ZALCITABINE$DB00943$true$effect$drug$Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.| 
DOXORUBICIN$DB00997$drug$Zanosar$DB00428$true$advise$brand$a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently. | 
DULOXETINE$DB00476$drug$AMITRIPTYLINE$DB00321$true$advise$drug$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| 
DULOXETINE$DB00476$drug$DESIPRAMINE$DB01151$true$mechanism$drug$When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.| 
DULOXETINE$DB00476$drug$FLUVOXAMINE$DB00176$true$mechanism$drug$Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.| 
DULOXETINE$DB00476$drug$IMIPRAMINE$DB00458$true$advise$drug$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| 
DULOXETINE$DB00476$drug$NORTRIPTYLINE$DB00540$true$advise$drug$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| 
Duragesic$DB00813$brand$ALCOHOL$DB00898$true$effect$drug$Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| 
EFAVIRENZ$DB00625$drug$Cancidas$DB00520$true$mechanism$brand$In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| 
Elspar$DB00023$brand$METHOTREXATE$DB00563$true$effect$drug$Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.| 
Enablex$DB00496$brand$CLARITHROMYCIN$DB01211$true$advise$drug$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| 
Enablex$DB00496$brand$Ketoconazole$DB01026$true$advise$drug$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| 
Enablex$DB00496$brand$NELFINAVIR$DB05251$true$advise$drug$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| 
Enablex$DB00496$brand$RITONAVIR$DB00503$true$advise$drug$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| 
ENALAPRIL$DB00584$drug$LITHIUM CATION$DB01356$true$advise$drug$It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.| 
ENALAPRIL$DB00584$drug$LITHIUM$DB01356$true$advise$drug$It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.| 
ENOXACIN$DB00467$drug$BISMUTH SUBSALICYLATE$DB01294$true$advise$drug$Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.| 
ENOXACIN$DB00467$drug$CAFFEINE$DB00201$true$mechanism$drug$In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.| 
ENOXACIN$DB00467$drug$DIGOXIN$DB00390$true$effect$drug$If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| Digoxin: Enoxacin may raise serum digoxin levels in some individuals.| 
ENOXACIN$DB00467$drug$DIGOXIN$DB00390$true$mechanism$drug$If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| Digoxin: Enoxacin may raise serum digoxin levels in some individuals.| 
ENOXACIN$DB00467$drug$RANITIDINE$DB00863$true$mechanism$drug$The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.| 
ENOXACIN$DB00467$drug$THEOPHYLLINE$DB00277$true$mechanism$drug$Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.| 
ENOXIMONE$DB04880$drug$ANAGRELIDE$DB00261$true$effect$drug$The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| 
EPA$DB00159$drug$ASPIRIN$DB00945$true$int$brand$Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).| 
EPHEDRINE$DB01364$drug$DEXMEDETOMIDINE$DB00633$true$effect$drug$Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.&#x0D;| 
EPHEDRINE$DB01364$drug$LEVOMEPROMAZINE$DB01403$true$effect$drug$Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. | 
EPHEDRINE$DB01364$drug$ProAmatine$DB00211$true$effect$brand$The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | 
EPINEPHRINE$DB00668$drug$GUANETHIDINE$DB01170$true$effect$drug$Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.| 
EPINEPHRINE$DB00668$drug$Isoproterenol$DB01064$true$advise$drug$Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.| 
EPLERENONE$DB00700$drug$ERYTHROMYCIN$DB00199$true$mechanism$drug$Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| 
EPLERENONE$DB00700$drug$FLUCONAZOLE$DB00196$true$mechanism$drug$Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| 
EPLERENONE$DB00700$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| 
EPLERENONE$DB00700$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| 
EPLERENONE$DB00700$drug$Verapamil$DB00661$true$mechanism$drug$Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.| 
Ergamisol$DB00848$brand$ALCOHOL$DB00898$true$effect$drug$ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.| 
Ergomar$DB00696$brand$Triacetyloleandomycin$DB01361$true$mechanism$drug$The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| 
ERGOTAMINE$DB00696$drug$Axert$DB00918$true$advise$brand$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| 
ERGOTAMINE$DB00696$drug$Frova$DB00998$true$advise$brand$Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| 
ERGOTAMINE$DB00696$drug$NARATRIPTAN$DB00952$true$advise$drug$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| 
ERGOTAMINE$DB00696$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
ERGOTAMINE$DB00696$drug$SUMATRIPTAN SUCCINATE$DB00669$true$advise$drug$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | 
ERGOTAMINE$DB00696$drug$SUMATRIPTAN$DB00669$true$advise$drug$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | 
ERTAPENEM$DB00303$drug$PROBENECID$DB01032$true$mechanism$drug$Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.| 
ERYTHROMYCIN$DB00199$drug$Alfenta$DB00802$true$mechanism$brand$Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.| 
ERYTHROMYCIN$DB00199$drug$ALFENTANIL$DB00802$true$int$drug$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$drug$ALMOTRIPTAN$DB00918$true$advise$drug$Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.| 
ERYTHROMYCIN$DB00199$drug$ASTEMIZOLE$DB00637$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.| 
ERYTHROMYCIN$DB00199$drug$ASTEMIZOLE$DB00637$true$mechanism$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.| 
ERYTHROMYCIN$DB00199$drug$BEXAROTENE$DB00307$true$mechanism$drug$On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| 
ERYTHROMYCIN$DB00199$drug$BROMOCRIPTINE$DB01200$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| 
ERYTHROMYCIN$DB00199$drug$CARBAMAZEPINE$DB00564$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| 
ERYTHROMYCIN$DB00199$drug$CILOSTAZOL$DB01166$true$mechanism$drug$Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.| 
ERYTHROMYCIN$DB00199$drug$Cisapride$DB00604$true$effect$drug$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$drug$Cisapride$DB00604$true$int$drug$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$drug$Cisapride$DB00604$true$mechanism$drug$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$drug$CLOZAPINE$DB00363$true$mechanism$drug$Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| 
ERYTHROMYCIN$DB00199$drug$CYCLOSPORINE$DB00091$true$int$drug$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$drug$DIGOXIN$DB00390$true$mechanism$drug$Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.| Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.| Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| 
ERYTHROMYCIN$DB00199$drug$DIHYDROERGOTAMINE$DB00320$true$effect$drug$Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| 
ERYTHROMYCIN$DB00199$drug$ERGOTAMINE$DB00696$true$effect$drug$Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| 
ERYTHROMYCIN$DB00199$drug$FENTANYL$DB00813$true$mechanism$drug$The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.| 
ERYTHROMYCIN$DB00199$drug$LORATADINE$DB00455$true$mechanism$drug$Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.| 
ERYTHROMYCIN$DB00199$drug$LOVASTATIN$DB00227$true$int$drug$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.| 
ERYTHROMYCIN$DB00199$drug$MIFEPRISTONE$DB00834$true$mechanism$drug$Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). | 
ERYTHROMYCIN$DB00199$drug$PHENYTOIN$DB00252$true$int$drug$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$drug$TACROLIMUS ANHYDROUS$DB00864$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$drug$TACROLIMUS$DB00864$true$int$drug$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$drug$THEOPHYLLINE$DB00277$true$effect$drug$Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.| 
ERYTHROMYCIN$DB00199$drug$TRIAZOLAM$DB00897$true$effect$drug$Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.| 
ERYTHROMYCIN$DB00199$drug$TRIAZOLAM$DB00897$true$mechanism$drug$Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.| 
ERYTHROMYCIN$DB00199$drug$Valproate$DB00313$true$int$drug$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$drug$VARDENAFIL$DB00862$true$mechanism$drug$Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.| 
ESCITALOPRAM OXALATE$DB01175$drug$Celexa$DB00215$true$advise$brand$Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.| 
ESCITALOPRAM OXALATE$DB01175$drug$DESIPRAMINE$DB01151$true$mechanism$drug$However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.| 
ESCITALOPRAM$DB01175$drug$Celexa$DB00215$true$advise$brand$Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.| 
ESCITALOPRAM$DB01175$drug$DESIPRAMINE$DB01151$true$mechanism$drug$However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.| 
ESOMEPRAZOLE$DB00736$drug$DIAZEPAM$DB00829$true$mechanism$drug$Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.| 
ESOMEPRAZOLE$DB00736$drug$DIGOXIN$DB00390$true$mechanism$drug$Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).| 
ESOMEPRAZOLE$DB00736$drug$IRON$DB01592$true$mechanism$drug$Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).| 
ESOMEPRAZOLE$DB00736$drug$Ketoconazole$DB01026$true$mechanism$drug$Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).| 
ESTAZOLAM$DB01215$drug$CARBAMAZEPINE$DB00564$true$mechanism$drug$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| 
ESTAZOLAM$DB01215$drug$ESTAZOLAM$DB01215$true$mechanism$drug$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| 
ESTAZOLAM$DB01215$drug$Ketoconazole$DB01026$true$advise$drug$Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.| 
ESTAZOLAM$DB01215$drug$PHENYTOIN$DB00252$true$mechanism$drug$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| 
ESTAZOLAM$DB01215$drug$RIFAMPIN$DB01045$true$mechanism$drug$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| 
ESTRADIOL$DB00783$drug$Noradrenaline$DB00368$true$effect$drug$Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). | Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). | 
ESZOPICLONE$DB00402$drug$ALCOHOL$DB00898$true$effect$drug$CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.| 
ESZOPICLONE$DB00402$drug$Ketoconazole$DB01026$true$mechanism$drug$The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.| 
ESZOPICLONE$DB00402$drug$OLANZAPINE$DB00334$true$effect$drug$Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.| 
ETHAMBUTOL$DB00330$drug$ALUMINUM HYDROXIDE$DB06723$true$advise$drug$The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.| It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.| 
ETHAMBUTOL$DB00330$drug$ALUMINUM HYDROXIDE$DB06723$true$mechanism$drug$The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.| It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.| 
ETHINYL ESTRADIOL$DB00977$drug$PREDNISOLONE$DB00860$true$mechanism$drug$Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.| 
ETHINYL ESTRADIOL$DB00977$drug$THEOPHYLLINE$DB00277$true$mechanism$drug$Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.| 
ETHIONAMIDE$DB00609$drug$CYCLOSERINE$DB00260$true$effect$drug$In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.| 
ETHOXZOLAMIDE$DB00311$drug$AMPHOTERICIN B$DB00681$true$effect$drug$Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.| 
ETHOXZOLAMIDE$DB00311$drug$PROCAINAMIDE$DB01035$true$effect$drug$Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.| 
ETHOXZOLAMIDE$DB00311$drug$QUINIDINE$DB00908$true$effect$drug$Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.| 
Etodolac$DB00749$drug$PHENYLBUTAZONE$DB00812$true$advise$drug$Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.| 
ETONOGESTREL$DB00294$drug$ACETAMINOPHEN$DB00316$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$ADENOSINE PHOSPHATE$DB00415$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Agenerase$DB00701$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$AMPICILLIN$DB00415$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$ASCORBIC ACID$DB00126$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$ATORVASTATIN$DB01076$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Atromid-S$DB00636$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$CLOFIBRATE$DB00636$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Crixivan$DB00224$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$CYCLOSPORINE$DB00091$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Dilantin$DB00252$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Felbatol$DB00949$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Fortovase$DB01232$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Gris-PEG$DB00400$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Invirase$DB01232$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Kadian$DB00295$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Lipitor$DB01076$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$MORPHINE$DB00295$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$MS Contin$DB00295$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Neoral $DB00091$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Nizoral$DB01026$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Norvir$DB00503$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$PHENOBARBITAL$DB01174$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$PHENYLBUTAZONE$DB00812$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$PREDNISOLONE$DB00860$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Prelone$DB00860$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Rifadin$DB01045$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$RIFAMPIN$DB01045$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Sandimmune $DB00091$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Sporanox$DB01167$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$TEGretol$DB00564$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$TETRACYCLINE$DB00759$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Theo-Dur$DB00277$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$THEOPHYLLINE$DB00277$true$int$drug$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Topamax$DB00273$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Trileptal$DB00776$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Tylenol$DB00316$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$drug$Viracept$DB00220$true$int$brand$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
Evista$DB00481$brand$CLOFIBRATE$DB00636$true$advise$drug$Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | 
Evista$DB00481$brand$DIAZEPAM$DB00829$true$advise$drug$Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | 
Evista$DB00481$brand$DIAZOXIDE$DB01119$true$advise$drug$Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | 
Evista$DB00481$brand$INDOMETHACIN$DB00328$true$advise$drug$Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | 
Evista$DB00481$brand$NAPROXEN$DB00788$true$advise$drug$Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. | 
Exjade$DB01609$brand$ALUMINUM$DB01370$true$advise$drug$Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.| 
EZETIMIBE$DB00973$drug$CYCLOSPORINE$DB00091$true$advise$drug$Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. | Patients who take both ezetimibe and cyclosporine should be carefully monitored. | 
EZETIMIBE$DB00973$drug$CYCLOSPORINE$DB00091$true$mechanism$drug$Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. | Patients who take both ezetimibe and cyclosporine should be carefully monitored. | 
Factive$DB01155$brand$CALCIUM CARBONATE$DB06724$true$mechanism$drug$Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.| 
Factive$DB01155$brand$CIMETIDINE$DB00501$true$mechanism$drug$Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.| 
Factive$DB01155$brand$PROBENECID$DB01032$true$mechanism$drug$Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.| 
Factive$DB01155$brand$PROGESTERONE$DB00396$true$mechanism$drug$Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.| 
FAMOTIDINE$DB00927$drug$CEFDITOREN PIVOXIL$DB01066$true$mechanism$drug$H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.| 
FAMOTIDINE$DB00927$drug$DASATINIB ANHYDROUS$DB01254$true$effect$drug$H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.| 
FAMOTIDINE$DB00927$drug$DASATINIB$DB01254$true$effect$drug$H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.| 
FELBAMATE$DB00949$drug$ETHINYL ESTRADIOL$DB00977$true$mechanism$drug$Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| 
FELBAMATE$DB00949$drug$GESTODENE$DB06730$true$mechanism$drug$Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.| 
FELBAMATE$DB00949$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.| 
FELBAMATE$DB00949$drug$PHENYTOIN$DB00252$true$advise$drug$In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.| Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.| 
FELBAMATE$DB00949$drug$PHENYTOIN$DB00252$true$mechanism$drug$In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.| Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.| 
FELBAMATE$DB00949$drug$Valproate$DB00313$true$mechanism$drug$Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.| 
Felbatol$DB00949$brand$CARBAMAZEPINE$DB00564$true$mechanism$drug$Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.| 
Felbatol$DB00949$brand$PHENYTOIN$DB00252$true$mechanism$drug$Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.| 
Felbatol$DB00949$brand$Valproate$DB00313$true$mechanism$drug$Valproate: Felbatol  causes an increase in steady-state valproate concentrations.| 
Feldene$DB00554$brand$ASPIRIN$DB00945$true$mechanism$brand$Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. | 
Feldene$DB00554$brand$LITHIUM CATION$DB01356$true$mechanism$drug$Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. | 
Feldene$DB00554$brand$LITHIUM$DB01356$true$mechanism$drug$Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. | 
Felodipine$DB01023$drug$CARBAMAZEPINE$DB00564$true$mechanism$drug$Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.| 
Felodipine$DB01023$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.| 
Felodipine$DB01023$drug$PHENYTOIN$DB00252$true$mechanism$drug$Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.| 
Femara$DB01006$brand$TAMOXIFEN$DB00675$true$mechanism$drug$(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.| 
FENOFIBRATE$DB01039$drug$ATORVASTATIN$DB01076$true$mechanism$drug$Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.| 
FENOFIBRATE$DB01039$drug$EZETIMIBE$DB00973$true$mechanism$drug$Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. | 
FENOFIBRATE$DB01039$drug$PRAVASTATIN$DB00175$true$mechanism$drug$Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.| 
FENOFIBRIC ACID$DB01039$drug$ATORVASTATIN$DB01076$true$mechanism$drug$Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.| 
FENOFIBRIC ACID$DB01039$drug$EZETIMIBE$DB00973$true$mechanism$drug$Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. | 
FENOFIBRIC ACID$DB01039$drug$PRAVASTATIN$DB00175$true$mechanism$drug$Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.| 
Fenoprofen$DB00573$drug$ASPIRIN$DB00945$true$mechanism$brand$Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.| 
FENTANYL$DB00813$drug$ALCOHOL$DB00898$true$effect$drug$Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| 
FENTANYL$DB00813$drug$CLARITHROMYCIN$DB01211$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
FENTANYL$DB00813$drug$Ketoconazole$DB01026$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
FENTANYL$DB00813$drug$NELFINAVIR$DB05251$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
FENTANYL$DB00813$drug$RITONAVIR$DB00503$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
FENTANYL$DB00813$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
FENTANYL$DB00813$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
FENTANYL$DB00813$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
FENTANYL$DB00813$drug$TROLEANDOMYCIN$DB01361$true$mechanism$drug$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
Flexeril$DB00924$brand$ALCOHOL$DB00898$true$effect$drug$FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.| 
Flomax$DB00706$brand$CIMETIDINE$DB00501$true$advise$drug$Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. | 
FLUCONAZOLE$DB00196$drug$ASTEMIZOLE$DB00637$true$mechanism$drug$Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. | 
FLUCONAZOLE$DB00196$drug$CELECOXIB$DB00482$true$mechanism$drug$Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.| 
FLUCONAZOLE$DB00196$drug$Cisapride$DB00604$true$advise$drug$The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| 
FLUCONAZOLE$DB00196$drug$Cisapride$DB00604$true$effect$drug$The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| 
FLUCONAZOLE$DB00196$drug$Cisapride$DB00604$true$mechanism$drug$The combined use of fluconazole with cisapride is contraindicated. | Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. | A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.| 
FLUCONAZOLE$DB00196$drug$ETHINYL ESTRADIOL$DB00977$true$mechanism$drug$While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. | Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; | 
FLUCONAZOLE$DB00196$drug$GLIPIZIDE$DB01067$true$int$drug$The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.| 
FLUCONAZOLE$DB00196$drug$LEVONORGESTREL$DB00367$true$mechanism$drug$Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; | While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. | 
FLUCONAZOLE$DB00196$drug$LOSARTAN$DB00678$true$mechanism$drug$Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.| 
FLUCONAZOLE$DB00196$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | 
FLUCONAZOLE$DB00196$drug$RIFABUTIN$DB00615$true$effect$drug$Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. | 
FLUCONAZOLE$DB00196$drug$TACROLIMUS ANHYDROUS$DB00864$true$effect$drug$Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. | 
FLUCONAZOLE$DB00196$drug$TACROLIMUS$DB00864$true$effect$drug$Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. | 
Fludara$DB01073$brand$PENTOSTATIN$DB00552$true$advise$drug$The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.| 
Fluothane$DB01159$brand$TUBOCURARINE$DB01199$true$effect$drug$FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.| 
Flupenthixol$DB00875$drug$ALCOHOL$DB00898$true$effect$drug$Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants| 
FLUPHENAZINE$DB00623$drug$CLONIDINE$DB00575$true$effect$drug$There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.| 
Flurbiprofen$DB00712$drug$ASPIRIN$DB00945$true$advise$brand$Concurrent use of flurbiprofen and aspirin is therefore not recommended.| 
Flurbiprofen$DB00712$drug$CIMETIDINE$DB00501$true$mechanism$drug$Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.| 
Flurbiprofen$DB00712$drug$FUROSEMIDE$DB00695$true$advise$drug$Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.| Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.| 
Flurbiprofen$DB00712$drug$FUROSEMIDE$DB00695$true$effect$drug$Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.| Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.| 
FLUVOXAMINE$DB00176$drug$ALOSETRON$DB00969$true$mechanism$drug$Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.| 
FLUVOXAMINE$DB00176$drug$ALPRAZOLAM$DB00404$true$int$drug$Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.| 
FLUVOXAMINE$DB00176$drug$ANAGRELIDE$DB00261$true$mechanism$drug$It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.| 
FLUVOXAMINE$DB00176$drug$ASTEMIZOLE$DB00637$true$advise$drug$Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| 
FLUVOXAMINE$DB00176$drug$Cisapride$DB00604$true$advise$drug$Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| 
FLUVOXAMINE$DB00176$drug$DIAZEPAM$DB00829$true$advise$drug$Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| 
FLUVOXAMINE$DB00176$drug$DIAZEPAM$DB00829$true$mechanism$drug$Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| 
FLUVOXAMINE$DB00176$drug$ROPIVACAINE$DB00296$true$int$drug$Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. | 
FLUVOXAMINE$DB00176$drug$SUMATRIPTAN SUCCINATE$DB00669$true$effect$drug$Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | 
FLUVOXAMINE$DB00176$drug$SUMATRIPTAN$DB00669$true$effect$drug$Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | 
FLUVOXAMINE$DB00176$drug$TERBINAFINE$DB00857$true$advise$drug$Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| 
FLUVOXAMINE$DB00176$drug$TOLBUTAMIDE$DB01124$true$mechanism$drug$Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.| RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. | 
FLUVOXAMINE$DB00176$drug$Xanax$DB00404$true$advise$brand$Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).| 
FOLIC ACID$DB00158$drug$PHENOBARBITAL$DB01174$true$effect$drug$Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.| 
FOLIC ACID$DB00158$drug$PHENYTOIN$DB00252$true$effect$drug$Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.| 
FOLIC ACID$DB00158$drug$PRIMIDONE$DB00794$true$effect$drug$Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.| 
FOLIC ACID$DB00158$drug$SULFASALAZINE$DB00795$true$mechanism$drug$Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. | 
FOSCARNET$DB00529$drug$HIVID$DB00943$true$effect$drug$Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| 
FOSCARNET$DB00529$drug$ZALCITABINE$DB00943$true$mechanism$drug$Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).| 
Foscavir$DB00529$brand$AMPHOTERICIN B$DB00681$true$advise$drug$Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| 
Foscavir$DB00529$brand$PENTAMIDINE$DB00738$true$advise$drug$A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| 
Foscavir$DB00529$brand$PENTAMIDINE$DB00738$true$effect$drug$A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| 
Foscavir$DB00529$brand$PENTAMIDINE$DB00738$true$int$drug$A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| 
FUROSEMIDE$DB00695$drug$ASPIRIN$DB00945$true$effect$drug$Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.| 
FUROSEMIDE$DB00695$drug$ETHACRYNIC ACID$DB00903$true$advise$drug$Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.| 
FUROSEMIDE$DB00695$drug$Flolan$DB01240$true$mechanism$brand$In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| 
FUROSEMIDE$DB00695$drug$Metolazone$DB00524$true$effect$drug$Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. | 
FUROSEMIDE$DB00695$drug$Mobic$DB00814$true$advise$brand$Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. | 
FUROSEMIDE$DB00695$drug$NOREPINEPHRINE$DB00368$true$effect$drug$Furosemide may decrease arterial responsiveness to norepinephrine.| 
FUROSEMIDE$DB00695$drug$SUCCINYLCHOLINE$DB00202$true$effect$drug$Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.| 
FUROSEMIDE$DB00695$drug$TUBOCURARINE$DB01199$true$effect$drug$Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.| 
GABAPENTIN$DB00996$drug$CIMETIDINE$DB00501$true$mechanism$drug$This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.| 
GEMFIBROZIL$DB01241$drug$BEXAROTENE$DB00307$true$mechanism$drug$On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| 
GEMFIBROZIL$DB01241$drug$Targretin$DB00307$true$advise$brand$Concomitant administration of gemfibrozil with Targretin capsules is not recommended.| 
Gleevec$DB00619$brand$CLARITHROMYCIN$DB01211$true$advise$drug$Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| 
Gleevec$DB00619$brand$CYCLOSPORINE$DB00091$true$advise$drug$Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).| 
Gleevec$DB00619$brand$ERYTHROMYCIN$DB00199$true$advise$drug$Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| 
Gleevec$DB00619$brand$Ketoconazole$DB01026$true$advise$drug$Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| 
Gleevec$DB00619$brand$Ketoconazole$DB01026$true$mechanism$drug$Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| 
Gleevec$DB00619$brand$PIMOZIDE$DB01100$true$advise$drug$Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).| 
Gleevec$DB00619$brand$SIMVASTATIN$DB00641$true$mechanism$drug$Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.| 
GLIMEPIRIDE$DB00222$drug$ASPIRIN$DB00945$true$advise$brand$Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| 
GLIMEPIRIDE$DB00222$drug$BISMUTH SUBSALICYLATE$DB01294$true$advise$drug$Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| 
GLIMEPIRIDE$DB00222$drug$Disalcid$DB01399$true$advise$brand$Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| 
GLIMEPIRIDE$DB00222$drug$MAGNESIUM SALICYLATE ANHYDROUS$DB01397$true$advise$drug$Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| 
GLIMEPIRIDE$DB00222$drug$MAGNESIUM SALICYLATE$DB01397$true$advise$drug$Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| 
GLIMEPIRIDE$DB00222$drug$Pepto-bismol$DB01294$true$advise$brand$Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| 
GLIMEPIRIDE$DB00222$drug$SALSALATE$DB01399$true$advise$drug$Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);| 
GLIPIZIDE$DB01067$drug$FLUCONAZOLE$DB00196$true$mechanism$drug$The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).| 
GLUTAMINE$DB00130$drug$INDOMETHACIN$DB00328$true$effect$drug$Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.| 
GLUTAMINE$DB00130$drug$PACLITAXEL$DB01229$true$effect$drug$Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.| 
GLYBURIDE$DB01016$drug$CIPROFLOXACIN$DB00537$true$int$drug$A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.| 
GLYBURIDE$DB01016$drug$VALDECOXIB$DB00580$true$advise$drug$Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.| 
GRISEOFULVIN$DB00400$drug$Levulan Kerastick$DB00855$true$effect$brand$It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.| 
GUANETHIDINE$DB01170$drug$MINOXIDIL$DB00350$true$advise$drug$If at all possible guanethidine should be discontinued well before minoxidil is begun. | 
GUANETHIDINE$DB01170$drug$Zebeta$DB00612$true$effect$brand$Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| 
GUANFACINE$DB01018$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.| 
GUANFACINE$DB01018$drug$PHENYTOIN$DB00252$true$mechanism$drug$The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.| 
Haldol$DB00502$brand$ALCOHOL$DB00898$true$effect$drug$As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.| 
HALOPERIDOL$DB00502$drug$DOPAMINE$DB00988$true$effect$drug$Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.| 
HALOPERIDOL$DB00502$drug$PCP$DB03575$true$effect$drug_n$Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. | 
HALOPERIDOL$DB00502$drug$RIFAMPIN$DB01045$true$mechanism$drug$In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.| 
HCTZ$DB00999$drug$DOFETILIDE$DB00204$true$mechanism$drug$In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.| 
Herceptin$DB00072$brand$LAPATINIB DITOSYLATE$DB01259$true$effect$drug$Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. | 
Herceptin$DB00072$brand$LAPATINIB$DB01259$true$effect$drug$Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. | 
Hexalen$DB00488$brand$CISPLATIN$DB00515$true$effect$drug$Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;| 
HISTIDINE$DB00117$drug$MEDROXYPROGESTERONE ACETATE$DB00603$true$effect$drug$Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.| 
HIVID$DB00943$drug$DIDANOSINE$DB00900$true$advise$drug$Concomitant use of HIVID with didanosine is not recommended.| 
HYDROCHLOROTHIAZIDE$DB00999$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
HYDROCODONE$DB00956$drug$GABAPENTIN$DB00996$true$mechanism$drug$Hydrocodone increases gabapentin AUC values by 14%.| 
Imiglucerase$DB06720$drug$Zavesca$DB00419$true$advise$brand$Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.| 
IMIPRAMINE$DB00458$drug$ALPRAZOLAM$DB00404$true$mechanism$drug$The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.| 
IMIPRAMINE$DB00458$drug$CIMETIDINE$DB00501$true$mechanism$drug$The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.| 
IMIPRAMINE$DB00458$drug$PHENYTOIN$DB00252$true$mechanism$drug$The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.| 
INAMRINONE$DB01427$drug$ANAGRELIDE$DB00261$true$effect$drug$The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| 
INDINAVIR ANHYDROUS$DB00224$drug$AMPRENAVIR$DB00701$true$mechanism$drug$Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.| 
INDINAVIR ANHYDROUS$DB00224$drug$Cisapride$DB00604$true$mechanism$drug$Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
INDINAVIR ANHYDROUS$DB00224$drug$DIDANOSINE$DB00900$true$advise$drug$Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. | Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.| Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| Median gastric pH was significantly higher when indinavir was taken after didanosine administration; | 
INDINAVIR ANHYDROUS$DB00224$drug$DIDANOSINE$DB00900$true$mechanism$drug$Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. | Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.| Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| Median gastric pH was significantly higher when indinavir was taken after didanosine administration; | 
INDINAVIR ANHYDROUS$DB00224$drug$EFAVIRENZ$DB00625$true$mechanism$drug$Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.| 
INDINAVIR ANHYDROUS$DB00224$drug$MEGESTROL ACETATE$DB00351$true$advise$drug$Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. | 
INDINAVIR ANHYDROUS$DB00224$drug$NEVIRAPINE$DB00238$true$mechanism$drug$Indinavir concentrations may be decreased in the presence of nevirapine.| 
INDINAVIR ANHYDROUS$DB00224$drug$RITONAVIR$DB00503$true$effect$drug$Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.| 
INDINAVIR ANHYDROUS$DB00224$drug$Sustiva$DB00625$true$mechanism$brand$When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.| Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.| 
INDINAVIR ANHYDROUS$DB00224$drug$VARDENAFIL$DB00862$true$mechanism$drug$HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.| 
INDINAVIR ANHYDROUS$DB00224$drug$Videx$DB00900$true$advise$brand$To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| 
INDINAVIR ANHYDROUS$DB00224$drug$Videx$DB00900$true$mechanism$brand$To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| 
INDINAVIR ANHYDROUS$DB00224$drug$Viracept$DB00220$true$mechanism$brand$Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.| 
INDINAVIR$DB00224$drug$AMPRENAVIR$DB00701$true$mechanism$drug$Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.| 
INDINAVIR$DB00224$drug$Cisapride$DB00604$true$mechanism$drug$Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
INDINAVIR$DB00224$drug$DIDANOSINE$DB00900$true$advise$drug$Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. | Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| Median gastric pH was significantly higher when indinavir was taken after didanosine administration; | Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.| 
INDINAVIR$DB00224$drug$DIDANOSINE$DB00900$true$mechanism$drug$Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. | Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| Median gastric pH was significantly higher when indinavir was taken after didanosine administration; | Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.| 
INDINAVIR$DB00224$drug$EFAVIRENZ$DB00625$true$mechanism$drug$Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.| 
INDINAVIR$DB00224$drug$MEGESTROL ACETATE$DB00351$true$advise$drug$Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. | 
INDINAVIR$DB00224$drug$NEVIRAPINE$DB00238$true$mechanism$drug$Indinavir concentrations may be decreased in the presence of nevirapine.| 
INDINAVIR$DB00224$drug$RITONAVIR$DB00503$true$effect$drug$Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.| 
INDINAVIR$DB00224$drug$Sustiva$DB00625$true$mechanism$brand$Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.| When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.| 
INDINAVIR$DB00224$drug$VARDENAFIL$DB00862$true$mechanism$drug$HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.| 
INDINAVIR$DB00224$drug$Videx$DB00900$true$advise$brand$To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| 
INDINAVIR$DB00224$drug$Videx$DB00900$true$mechanism$brand$To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| 
INDINAVIR$DB00224$drug$Viracept$DB00220$true$mechanism$brand$Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.| 
Indocin$DB00328$brand$CAPTOPRIL$DB01197$true$effect$drug$INDOCIN can reduce the antihypertensive effects of captopril and losartan.| 
Indocin$DB00328$brand$DIFLUNISAL$DB00861$true$effect$drug$In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.| 
Indocin$DB00328$brand$DIGOXIN$DB00390$true$advise$drug$Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.| INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.| 
Indocin$DB00328$brand$DIGOXIN$DB00390$true$mechanism$drug$Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.| INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.| 
Indocin$DB00328$brand$LITHIUM CATION$DB01356$true$advise$drug$As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.| Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.| 
Indocin$DB00328$brand$LITHIUM CATION$DB01356$true$mechanism$drug$As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.| Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.| 
Indocin$DB00328$brand$LITHIUM$DB01356$true$advise$drug$As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.| Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.| 
Indocin$DB00328$brand$LITHIUM$DB01356$true$mechanism$drug$As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.| Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.| 
Indocin$DB00328$brand$LOSARTAN$DB00678$true$effect$drug$INDOCIN can reduce the antihypertensive effects of captopril and losartan.| 
Indocin$DB00328$brand$METHOTREXATE$DB00563$true$advise$drug$INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.| Caution should be used if INDOCIN is administered simultaneously with methotrexate.| 
Indocin$DB00328$brand$METHOTREXATE$DB00563$true$mechanism$drug$INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.| Caution should be used if INDOCIN is administered simultaneously with methotrexate.| 
Indocin$DB00328$brand$PROBENECID$DB01032$true$mechanism$drug$When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.| 
Indocin$DB00328$brand$TRIAMTERENE$DB00384$true$advise$drug$INDOCIN and triamterene should not be administered together.| 
INDOMETHACIN$DB00328$drug$BUMETANIDE$DB00887$true$effect$drug$- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| - Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| 
INDOMETHACIN$DB00328$drug$BUMETANIDE$DB00887$true$mechanism$drug$- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| - Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| 
INDOMETHACIN$DB00328$drug$CAPTOPRIL$DB01197$true$effect$drug$Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.| 
INDOMETHACIN$DB00328$drug$DIFLUNISAL$DB00861$true$advise$drug$In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.| Therefore, indomethacin and diflunisal should not be used concomitantly.| 
INDOMETHACIN$DB00328$drug$DIFLUNISAL$DB00861$true$effect$drug$In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.| Therefore, indomethacin and diflunisal should not be used concomitantly.| 
INDOMETHACIN$DB00328$drug$DIGOXIN$DB00390$true$mechanism$drug$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
INDOMETHACIN$DB00328$drug$FUROSEMIDE$DB00695$true$advise$drug$Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.| Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.| 
INDOMETHACIN$DB00328$drug$FUROSEMIDE$DB00695$true$effect$drug$Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.| Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.| 
INDOMETHACIN$DB00328$drug$Midamor$DB00594$true$effect$brand$Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.| 
INDOMETHACIN$DB00328$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
INDOMETHACIN$DB00328$drug$Proleukin$DB00041$true$effect$brand$Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.| 
INH$DB00951$drug$Ketoconazole$DB01026$true$mechanism$drug$INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| 
INSPRA$DB00700$brand$ENALAPRIL$DB00584$true$effect$drug$In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.| 
INSPRA$DB00700$brand$Ketoconazole$DB01026$true$mechanism$drug$A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.| 
INSPRA$DB00700$brand$LITHIUM CATION$DB01356$true$advise$drug$Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.| 
INSPRA$DB00700$brand$LITHIUM$DB01356$true$advise$drug$Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.| 
Invega$DB01267$brand$ALCOHOL$DB00898$true$advise$drug$Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. | 
Invirase$DB01232$brand$RITONAVIR$DB00503$true$advise$drug$Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.| 
IODINE$DB05382$drug$CARBIMAZOLE$DB00389$true$effect$drug$Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.| 
Iopidine$DB00964$brand$ALCOHOL$DB00898$true$advise$drug$Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.| 
IRBESARTAN$DB01029$drug$ALISKIREN$DB01258$true$mechanism$drug$Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.| 
Iressa$DB00317$brand$VINORELBINE$DB00361$true$effect$drug$Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.| 
IRON$DB01592$drug$CARBIDOPA$DB00190$true$mechanism$drug$Iron salts may reduce the bioavailability of carbidopa and levodopa.| 
IRON$DB01592$drug$Factive$DB01155$true$advise$brand$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| 
IRON$DB01592$drug$IBANDRONIC ACID$DB00710$true$mechanism$drug$Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| 
IRON$DB01592$drug$LEVODOPA$DB01235$true$mechanism$drug$Iron salts may reduce the bioavailability of carbidopa and levodopa.| 
IRON$DB01592$drug$NORFLOXACIN$DB01059$true$advise$drug$Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| 
ISOCARBOXAZID$DB01247$drug$Antabuse$DB00822$true$advise$brand$Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).| 
ISOCARBOXAZID$DB01247$drug$DISULFIRAM$DB00822$true$advise$drug$Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).| 
Isoflurane$DB00753$drug$Nimbex$DB00565$true$advise$brand$Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.| In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| 
Isoflurane$DB00753$drug$Nimbex$DB00565$true$effect$brand$Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.| In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| 
Isoflurane$DB00753$drug$Nuromax$DB01135$true$mechanism$brand$Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.| 
ISONIAZID$DB00951$drug$ACETAMINOPHEN$DB00316$true$effect$drug$It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.| Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.| 
ISONIAZID$DB00951$drug$ACETAMINOPHEN$DB00316$true$mechanism$drug$It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.| Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.| 
ISONIAZID$DB00951$drug$CARBAMAZEPINE$DB00564$true$mechanism$drug$Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.| 
ISONIAZID$DB00951$drug$DISULFIRAM$DB00822$true$advise$drug$Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;| 
ISONIAZID$DB00951$drug$Ketoconazole$DB01026$true$mechanism$drug$INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| 
ISONIAZID$DB00951$drug$LEVODOPA$DB01235$true$effect$drug$Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.| 
ISONIAZID$DB00951$drug$PHENYTOIN$DB00252$true$mechanism$drug$Phenytoin: Isoniazid may increase serum levels of phenytoin.| 
ISONIAZID$DB00951$drug$THEOPHYLLINE$DB00277$true$mechanism$drug$Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.| 
ISONIAZID$DB00951$drug$Valproate$DB00313$true$advise$drug$Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.| 
ISOPENTYL NITRITE$DB01612$drug$ALCOHOL$DB00898$true$effect$drug$Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.| 
Isopto Carbachol$DB00411$brand$Suprofen$DB00870$true$effect$drug$Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.| 
KAOLIN$DB01575$drug$DIGOXIN$DB00390$true$mechanism$drug$Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| 
Ketoconazole$DB01026$drug$ALISKIREN$DB01258$true$mechanism$drug$Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.| 
Ketoconazole$DB01026$drug$ALOSETRON$DB00969$true$mechanism$drug$Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.| 
Ketoconazole$DB01026$drug$ARIPIPRAZOLE$DB01238$true$advise$drug$When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| 
Ketoconazole$DB01026$drug$ARIPIPRAZOLE$DB01238$true$mechanism$drug$When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| 
Ketoconazole$DB01026$drug$ASTEMIZOLE$DB00637$true$effect$drug$Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.| Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| 
Ketoconazole$DB01026$drug$ASTEMIZOLE$DB00637$true$mechanism$drug$Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.| Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| 
Ketoconazole$DB01026$drug$BEXAROTENE$DB00307$true$mechanism$drug$On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| 
Ketoconazole$DB01026$drug$CICLESONIDE$DB01410$true$advise$drug$Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.| 
Ketoconazole$DB01026$drug$CINACALCET$DB01012$true$mechanism$drug$Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.| 
Ketoconazole$DB01026$drug$Cisapride$DB00604$true$advise$drug$Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| 
Ketoconazole$DB01026$drug$Cisapride$DB00604$true$effect$drug$Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| 
Ketoconazole$DB01026$drug$Cisapride$DB00604$true$mechanism$drug$Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| 
Ketoconazole$DB01026$drug$COUMARIN$DB04665$true$effect$group$When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.| 
Ketoconazole$DB01026$drug$CYCLOSPORINE$DB00091$true$mechanism$drug$Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| 
Ketoconazole$DB01026$drug$ERLOTINIB$DB00530$true$mechanism$drug$Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.| 
Ketoconazole$DB01026$drug$GEFITINIB$DB00317$true$mechanism$drug$Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.| 
Ketoconazole$DB01026$drug$ISONIAZID$DB00951$true$int$drug$Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.| 
Ketoconazole$DB01026$drug$LAPATINIB DITOSYLATE$DB01259$true$mechanism$drug$Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.| 
Ketoconazole$DB01026$drug$LAPATINIB$DB01259$true$mechanism$drug$Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.| 
Ketoconazole$DB01026$drug$LORATADINE$DB00455$true$mechanism$drug$After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.| 
Ketoconazole$DB01026$drug$METHYLPREDNISOLONE$DB00959$true$mechanism$drug$Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. | 
Ketoconazole$DB01026$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | 
Ketoconazole$DB01026$drug$MIFEPRISTONE$DB00834$true$mechanism$drug$Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). | 
Ketoconazole$DB01026$drug$MOMETASONE FUROATE$DB00764$true$mechanism$drug$However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.| 
Ketoconazole$DB01026$drug$PARICALCITOL$DB00910$true$mechanism$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
Ketoconazole$DB01026$drug$PHENYTOIN$DB00252$true$advise$drug$It is suggested to monitor both ketoconazole and phenytoin.| Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.| 
Ketoconazole$DB01026$drug$PHENYTOIN$DB00252$true$mechanism$drug$It is suggested to monitor both ketoconazole and phenytoin.| Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.| 
Ketoconazole$DB01026$drug$RETAPAMULIN$DB01256$true$mechanism$drug$Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. | 
Ketoconazole$DB01026$drug$ROPIVACAINE$DB00296$true$mechanism$drug$Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.| 
Ketoconazole$DB01026$drug$TACROLIMUS ANHYDROUS$DB00864$true$mechanism$drug$Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| 
Ketoconazole$DB01026$drug$TACROLIMUS$DB00864$true$mechanism$drug$Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| 
Ketoconazole$DB01026$drug$Tikosyn$DB00204$true$mechanism$brand$Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.| 
Ketoconazole$DB01026$drug$TOLTERODINE$DB01036$true$mechanism$drug$CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). | 
Ketoconazole$DB01026$drug$TRIMETREXATE$DB01157$true$mechanism$drug$Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. | 
Ketoconazole$DB01026$drug$VARDENAFIL$DB00862$true$mechanism$drug$Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.| 
Ketoconazole$DB01026$drug$Videx$DB00900$true$advise$brand$Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.| 
Ketoconazole$DB01026$drug$Viracept$DB00220$true$mechanism$brand$Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.| 
Ketoconazole$DB01026$drug$ZALEPLON$DB00962$true$mechanism$drug$Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.| 
LAMIVUDINE$DB00709$drug$ZALCITABINE$DB00943$true$advise$drug$Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.| Therefore, use of lamivudine in combination with zalcitabine is not recommended| 
LAMIVUDINE$DB00709$drug$ZALCITABINE$DB00943$true$effect$drug$Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.| Therefore, use of lamivudine in combination with zalcitabine is not recommended| 
Lansoprazole$DB00448$drug$ADENOSINE PHOSPHATE$DB00415$true$mechanism$drug$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| 
Lansoprazole$DB00448$drug$AMPICILLIN$DB00415$true$mechanism$drug$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| 
Lansoprazole$DB00448$drug$DIGOXIN$DB00390$true$mechanism$drug$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| 
Lansoprazole$DB00448$drug$IRON$DB01592$true$mechanism$drug$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| 
Lansoprazole$DB00448$drug$Ketoconazole$DB01026$true$mechanism$drug$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| 
Lansoprazole$DB00448$drug$THEOPHYLLINE$DB00277$true$mechanism$drug$When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.| 
LAPATINIB DITOSYLATE$DB01259$drug$Herceptin$DB00072$true$effect$brand$In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. | Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.&#x0D;| Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.| 
LAPATINIB$DB01259$drug$Herceptin$DB00072$true$effect$brand$In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. | Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.&#x0D;| Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.| 
Leukine$DB00020$brand$LITHIUM CATION$DB01356$true$effect$drug$Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.| 
Leukine$DB00020$brand$LITHIUM$DB01356$true$effect$drug$Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.| 
LEVOBUPIVACAINE$DB01002$drug$Ketoconazole$DB01026$true$mechanism$drug$Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| 
LEVOBUPIVACAINE$DB01002$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| 
LEVOBUPIVACAINE$DB01002$drug$PHENYTOIN$DB00252$true$mechanism$drug$Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| 
LEVOBUPIVACAINE$DB01002$drug$RIFAMPIN$DB01045$true$mechanism$drug$Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| 
LEVODOPA$DB01235$drug$PAPAVERINE$DB01113$true$effect$drug$In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.| 
LEVODOPA$DB01235$drug$PHENYTOIN$DB00252$true$effect$drug$In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.| 
Levo-Dromoran$DB00854$brand$ALCOHOL$DB00898$true$effect$drug$Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.| 
LEVOTHYROXINE$DB00451$drug$Estrogens$DB00286$true$mechanism$group$In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.| 
Levsin$DB00424$brand$AMANTADINE$DB00915$true$effect$drug$Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.| 
Levsin$DB00424$brand$HALOPERIDOL$DB00502$true$effect$drug$Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.| 
Lexapro$DB01175$brand$LITHIUM CATION$DB01356$true$advise$drug$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| 
Lexapro$DB01175$brand$LITHIUM$DB01356$true$advise$drug$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| 
LINCOMYCIN$DB01627$drug$ERYTHROMYCIN$DB00199$true$effect$drug$Antagonism between lincomycin and erythromycin in vitro has been demonstrated.| 
LITHIUM CATION$DB01356$drug$Atacand$DB00796$true$mechanism$brand$An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.| 
LITHIUM CATION$DB01356$drug$BUMETANIDE$DB00887$true$advise$drug$- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.| 
LITHIUM CATION$DB01356$drug$Celebrex$DB00482$true$advise$brand$Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| 
LITHIUM CATION$DB01356$drug$Celebrex$DB00482$true$mechanism$brand$Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| 
LITHIUM CATION$DB01356$drug$CHLOROTHIAZIDE$DB00880$true$advise$drug$Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide| 
LITHIUM CATION$DB01356$drug$ESCITALOPRAM OXALATE$DB01175$true$effect$drug$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| 
LITHIUM CATION$DB01356$drug$ESCITALOPRAM$DB01175$true$effect$drug$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| 
LITHIUM CATION$DB01356$drug$Feldene$DB00554$true$advise$brand$It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.| 
LITHIUM CATION$DB01356$drug$Haldol$DB00502$true$effect$brand$An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.| 
LITHIUM CATION$DB01356$drug$HYDROCHLOROTHIAZIDE$DB00999$true$advise$drug$Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.| 
LITHIUM CATION$DB01356$drug$MELOXICAM$DB00814$true$mechanism$drug$In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. | 
LITHIUM CATION$DB01356$drug$Mobic$DB00814$true$advise$brand$Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. | 
LITHIUM CATION$DB01356$drug$Neulasta$DB00019$true$advise$brand$patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.| 
LITHIUM CATION$DB01356$drug$Toradol$DB00465$true$mechanism$brand$The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.| 
LITHIUM$DB01356$drug$Atacand$DB00796$true$mechanism$brand$An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.| 
LITHIUM$DB01356$drug$BUMETANIDE$DB00887$true$advise$drug$- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.| 
LITHIUM$DB01356$drug$Celebrex$DB00482$true$advise$brand$Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| 
LITHIUM$DB01356$drug$Celebrex$DB00482$true$mechanism$brand$Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| 
LITHIUM$DB01356$drug$CHLOROTHIAZIDE$DB00880$true$advise$drug$Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide| 
LITHIUM$DB01356$drug$ESCITALOPRAM OXALATE$DB01175$true$effect$drug$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| 
LITHIUM$DB01356$drug$ESCITALOPRAM$DB01175$true$effect$drug$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| 
LITHIUM$DB01356$drug$Feldene$DB00554$true$advise$brand$It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.| 
LITHIUM$DB01356$drug$Haldol$DB00502$true$effect$brand$An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.| 
LITHIUM$DB01356$drug$HYDROCHLOROTHIAZIDE$DB00999$true$advise$drug$Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.| 
LITHIUM$DB01356$drug$MELOXICAM$DB00814$true$mechanism$drug$In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. | 
LITHIUM$DB01356$drug$Mobic$DB00814$true$advise$brand$Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. | 
LITHIUM$DB01356$drug$Neulasta$DB00019$true$advise$brand$patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.| 
LITHIUM$DB01356$drug$Toradol$DB00465$true$mechanism$brand$The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.| 
Lodine$DB00749$brand$ASPIRIN$DB00945$true$advise$brand$Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| 
Lodine$DB00749$brand$ASPIRIN$DB00945$true$mechanism$brand$Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| 
Lodine$DB00749$brand$CYCLOSPORINE$DB00091$true$mechanism$drug$Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.| 
Lodine$DB00749$brand$DIGOXIN$DB00390$true$mechanism$drug$Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.| 
Lodine$DB00749$brand$FUROSEMIDE$DB00695$true$effect$drug$Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.| 
Lodine$DB00749$brand$METHOTREXATE$DB00563$true$mechanism$drug$Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.| 
LOPINAVIR$DB01601$drug$NEVIRAPINE$DB00238$true$advise$drug$A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.| 
LOPINAVIR$DB01601$drug$Sustiva$DB00625$true$advise$brand$A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.| 
LORACARBEF ANHYDROUS$DB00447$drug$PROBENECID$DB01032$true$mechanism$drug$Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.| 
LORACARBEF$DB00447$drug$PROBENECID$DB01032$true$mechanism$drug$Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.| 
LOSARTAN$DB00678$drug$INDOMETHACIN$DB00328$true$effect$drug$As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin| 
LOVASTATIN$DB00227$drug$ERYTHROMYCIN$DB00199$true$advise$drug$Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;| 
LYMECYCLINE$DB00256$drug$IRON$DB01592$true$mechanism$drug$The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.| 
LYMECYCLINE$DB00256$drug$ZINC$DB01593$true$mechanism$drug$The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.| 
MAGNESIUM CATION$DB01378$drug$Factive$DB01155$true$advise$brand$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| 
MAGNESIUM CATION$DB01378$drug$IBANDRONIC ACID$DB00710$true$mechanism$drug$Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| 
MAGNESIUM CATION$DB01378$drug$Skelid$DB01133$true$mechanism$brand$The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | 
MAGNESIUM CATION$DB01378$drug$Videx$DB00900$true$effect$brand$Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.| 
MAGNESIUM$DB01378$drug$Factive$DB01155$true$advise$brand$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| 
MAGNESIUM$DB01378$drug$IBANDRONIC ACID$DB00710$true$mechanism$drug$Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.| 
MAGNESIUM$DB01378$drug$Skelid$DB01133$true$mechanism$brand$The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | 
MAGNESIUM$DB01378$drug$Videx$DB00900$true$effect$brand$Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.| 
Mazindol$DB00579$drug$GUANETHIDINE$DB01170$true$effect$drug$Mazindol may reduce the effects of guanethidine (Ismelin). | 
Mazindol$DB00579$drug$Ismelin$DB01170$true$effect$brand$Mazindol may reduce the effects of guanethidine (Ismelin). | 
Mazindol$DB00579$drug$ISOCARBOXAZID$DB01247$true$advise$drug$You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | 
Mazindol$DB00579$drug$Marplan$DB01247$true$advise$brand$You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | 
Mazindol$DB00579$drug$Nardil$DB00780$true$advise$brand$You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | 
Mazindol$DB00579$drug$Parnate$DB00752$true$advise$brand$You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | 
Mazindol$DB00579$drug$PHENELZINE$DB00780$true$advise$drug$You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | 
Mazindol$DB00579$drug$Tranylcypromine$DB00752$true$advise$drug$You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. | 
MEGESTROL ACETATE$DB00351$drug$INDINAVIR ANHYDROUS$DB00224$true$mechanism$drug$A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. | 
MEGESTROL ACETATE$DB00351$drug$INDINAVIR$DB00224$true$mechanism$drug$A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. | 
MELATONIN$DB01065$drug$ASPIRIN$DB00945$true$int$brand$Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).| 
MELATONIN$DB01065$drug$FLUVOXAMINE$DB00176$true$int$drug$Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).| 
MELOXICAM$DB00814$drug$ASPIRIN$DB00945$true$advise$brand$however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. | 
MEPERIDINE$DB00454$drug$ALCOHOL$DB00898$true$advise$drug$Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). | 
MERCAPTOPURINE$DB01033$drug$Tabloid$DB00352$true$effect$brand$There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. | 
MEROPENEM ANHYDROUS$DB00760$drug$DIPHENOLIC ACID$DB00313$true$mechanism$drug$There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| 
MEROPENEM ANHYDROUS$DB00760$drug$VALPROIC ACID$DB00313$true$mechanism$drug$There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| 
MEROPENEM$DB00760$drug$DIPHENOLIC ACID$DB00313$true$mechanism$drug$There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| 
MEROPENEM$DB00760$drug$VALPROIC ACID$DB00313$true$mechanism$drug$There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).| 
METFORMIN$DB00331$drug$DOFETILIDE$DB00204$true$advise$drug$In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| 
METHAMPHETAMINE$DB01577$drug$PARGYLINE$DB01626$true$effect$drug$Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. | 
METHIONINE$DB00134$drug$ACETAMINOPHEN$DB00316$true$effect$drug$Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.| 
METHIONINE$DB00134$drug$METHOTREXATE$DB00563$true$effect$drug$Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.| 
METHOTREXATE$DB00563$drug$ACITRETIN$DB00459$true$advise$drug$Consequently, the combination of methotrexate with acitretin is also contraindicated.| 
METHOTREXATE$DB00563$drug$CIPROFLOXACIN$DB00537$true$advise$drug$Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.| Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.| 
METHOTREXATE$DB00563$drug$CIPROFLOXACIN$DB00537$true$mechanism$drug$Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.| Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.| 
METHOTREXATE$DB00563$drug$Elspar$DB00023$true$advise$brand$These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.| 
METHOTREXATE$DB00563$drug$ETRETINATE$DB00926$true$effect$drug$Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.| 
METHOTREXATE$DB00563$drug$GLUTAMINE$DB00130$true$effect$drug$In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.| Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.| 
METHOTREXATE$DB00563$drug$Proleukin$DB00041$true$effect$brand$Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.| 
METHOTREXATE$DB00563$drug$ROFECOXIB$DB00533$true$mechanism$drug$At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).| 
METHOTREXATE$DB00563$drug$SULFAPYRIDINE$DB00891$true$effect$drug$- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate| 
METHOTREXATE$DB00563$drug$TENIPOSIDE$DB00444$true$mechanism$drug$An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.| 
METHYLDOPA$DB00968$drug$LITHIUM CATION$DB01356$true$advise$drug$When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. | 
METHYLDOPA$DB00968$drug$LITHIUM$DB01356$true$advise$drug$When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. | 
METHYLDOPA$DB00968$drug$SULFAPYRIDINE$DB00891$true$effect$drug$- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood| 
METHYLPREDNISOLONE$DB00959$drug$APREPITANT$DB00673$true$advise$drug$The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.| 
METHYLPREDNISOLONE$DB00959$drug$ASPIRIN$DB00945$true$mechanism$brand$Methylprednisolone may increase the clearance of chronic high dose aspirin. | 
METHYSERGIDE$DB00247$drug$Axert$DB00918$true$advise$brand$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.| 
METHYSERGIDE$DB00247$drug$Frova$DB00998$true$advise$brand$Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| 
METHYSERGIDE$DB00247$drug$NARATRIPTAN$DB00952$true$advise$drug$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| 
METHYSERGIDE$DB00247$drug$SUMATRIPTAN SUCCINATE$DB00669$true$advise$drug$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | 
METHYSERGIDE$DB00247$drug$SUMATRIPTAN$DB00669$true$advise$drug$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. | 
METOCLOPRAMIDE$DB01233$drug$ACETAMINOPHEN$DB00316$true$mechanism$drug$Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). | 
METOCLOPRAMIDE$DB01233$drug$ALCOHOL$DB00898$true$effect$drug$Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. | 
METOCLOPRAMIDE$DB01233$drug$Apokyn$DB00714$true$effect$brand$Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.| 
METOCLOPRAMIDE$DB01233$drug$DIGOXIN$DB00390$true$mechanism$drug$Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| 
METOCLOPRAMIDE$DB01233$drug$LEVODOPA$DB01235$true$mechanism$drug$Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.| 
METOCLOPRAMIDE$DB01233$drug$Permax$DB01186$true$advise$brand$Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); | 
METOCLOPRAMIDE$DB01233$group$Mirapex$DB00413$true$effect$brand$Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. | 
Metolazone$DB00524$drug$NOREPINEPHRINE$DB00368$true$effect$drug$Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. | 
Metopirone$DB01011$brand$ACETAMINOPHEN$DB00316$true$effect$drug$Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.| Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.| 
Metopirone$DB01011$brand$ACETAMINOPHEN$DB00316$true$mechanism$drug$Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.| Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.| 
Metopirone$DB01011$brand$PHENYTOIN$DB00252$true$mechanism$drug$The metabolism of Metopirone is accelerated by phenytoin; | 
METRONIDAZOLE$DB00916$drug$COUMARIN$DB04665$true$effect$group$Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. | 
Mexitil$DB00379$brand$THEOPHYLLINE$DB00277$true$advise$drug$This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. | Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. | 
Mexitil$DB00379$brand$THEOPHYLLINE$DB00277$true$mechanism$drug$This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. | Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. | 
MIDAZOLAM$DB00683$drug$APREPITANT$DB00673$true$advise$drug$The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| 
MIDAZOLAM$DB00683$drug$CYCLOSPORINE$DB00091$true$mechanism$drug$Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). | 
MIDAZOLAM$DB00683$drug$DILTIAZEM$DB00343$true$mechanism$drug$The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.| 
MIDAZOLAM$DB00683$drug$FLUCONAZOLE$DB00196$true$effect$drug$This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. | Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. | 
MIDAZOLAM$DB00683$drug$FLUCONAZOLE$DB00196$true$mechanism$drug$This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. | Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. | 
MIDAZOLAM$DB00683$drug$FLUVOXAMINE$DB00176$true$mechanism$drug$Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| 
MIDAZOLAM$DB00683$drug$INDOMETHACIN$DB00328$true$effect$drug$Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.| 
MIDAZOLAM$DB00683$drug$MORPHINE$DB00295$true$effect$drug$Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.| 
MILRINONE$DB00235$drug$ANAGRELIDE$DB00261$true$effect$drug$The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| 
MINOCYCLINE$DB01017$drug$FOSFOMYCIN$DB00828$true$effect$drug$The combination of minocycline and fosfomycin can be synergistic against MRSA. | 
MINOXIDIL$DB00350$drug$GUANETHIDINE$DB01170$true$effect$drug$Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. | 
Mivacron$DB01226$brand$BACITRACIN A$DB00626$true$int$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | 
Mivacron$DB01226$brand$CLINDAMYCIN$DB01190$true$int$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | 
Mivacron$DB01226$brand$Colistin$DB00803$true$int$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | 
Mivacron$DB01226$brand$LINCOMYCIN$DB01627$true$int$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | 
Mivacron$DB01226$brand$LITHIUM CATION$DB01356$true$int$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | 
Mivacron$DB01226$brand$LITHIUM$DB01356$true$int$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | 
Mivacron$DB01226$brand$MAGNESIUM CATION$DB01378$true$int$group$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | 
Mivacron$DB01226$brand$MAGNESIUM$DB01378$true$int$group$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | 
Mivacron$DB01226$brand$PROCAINAMIDE$DB01035$true$int$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | 
Mivacron$DB01226$brand$QUINIDINE$DB00908$true$int$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. | 
MOCLOBEMIDE$DB01171$drug$ALMOTRIPTAN$DB00918$true$mechanism$drug$Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.| 
Monurol$DB00828$brand$METOCLOPRAMIDE$DB01233$true$mechanism$drug$Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.| 
MORPHINE$DB00295$drug$ADL 8-2698$DB06274$true$effect$drug$Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004). | 
MORPHINE$DB00295$drug$ALCOHOL$DB00898$true$effect$drug$Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. | 
MORPHINE$DB00295$drug$Neurontin$DB00996$true$mechanism$brand$Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.| 
MOXIFLOXACIN$DB00218$drug$ERYTHROMYCIN$DB00199$true$mechanism$drug$Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. | 
Myfortic$DB01024$brand$ALUMINUM$DB01370$true$mechanism$drug$Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. | 
Myfortic$DB01024$brand$AZATHIOPRINE$DB00993$true$advise$drug$Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. | 
Myfortic$DB01024$brand$MAGNESIUM CATION$DB01378$true$mechanism$drug$Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. | 
Myfortic$DB01024$brand$MAGNESIUM$DB01378$true$mechanism$drug$Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. | 
Myfortic$DB01024$brand$MYCOPHENOLATE MOFETIL$DB00688$true$advise$drug$Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. | 
Nabilone$DB00486$drug$ALCOHOL$DB00898$true$advise$drug$Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| 
Nabilone$DB00486$drug$ALCOHOL$DB00898$true$effect$drug$Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| 
Nabilone$DB00486$drug$CODEINE$DB00318$true$effect$drug$Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| 
Nabilone$DB00486$drug$DIAZEPAM$DB00829$true$effect$drug$Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| 
NALBUPHINE$DB00844$drug$Levo-Dromoran$DB00854$true$advise$brand$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| 
NALIDIXIC ACID$DB00779$drug$MELPHALAN$DB01042$true$effect$drug$DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  | 
NALOXONE$DB01183$drug$MORPHINE$DB00295$true$effect$drug$Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. | the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. | On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). | 
NALTREXONE$DB00704$drug$ACAMPROSATE$DB00659$true$mechanism$drug$Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.| 
NAPROXEN$DB00788$drug$ASPIRIN$DB00945$true$advise$brand$Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.| 
NAPROXEN$DB00788$drug$METHOTREXATE$DB00563$true$advise$drug$Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.| Caution should be used if naproxen is administered concomitantly with methotrexate.| 
NAPROXEN$DB00788$drug$METHOTREXATE$DB00563$true$mechanism$drug$Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.| Caution should be used if naproxen is administered concomitantly with methotrexate.| 
NEFAZODONE$DB01149$drug$Cisapride$DB00604$true$mechanism$drug$Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
NELFINAVIR$DB05251$drug$AMPRENAVIR$DB00701$true$mechanism$drug$Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.| 
NELFINAVIR$DB05251$drug$DIDANOSINE$DB00900$true$advise$drug$therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.| 
NELFINAVIR$DB05251$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. | 
NETILMICIN$DB00955$drug$ETHACRYNIC ACID$DB00903$true$advise$drug$Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.| 
NETILMICIN$DB00955$drug$FUROSEMIDE$DB00695$true$advise$drug$Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.| 
NEVIRAPINE$DB00238$drug$Cancidas$DB00520$true$mechanism$brand$In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| 
NEVIRAPINE$DB00238$drug$Ketoconazole$DB01026$true$advise$drug$Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.| 
NEVIRAPINE$DB00238$drug$RIFAMPIN$DB01045$true$advise$drug$Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.| 
Nexavar$DB00398$brand$DOXORUBICIN$DB00997$true$mechanism$drug$Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. | 
Nexavar$DB00398$brand$IRINOTECAN$DB00762$true$advise$drug$Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). | 
NICOTINE$DB00184$drug$CLOZAPINE$DB00363$true$mechanism$drug$Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.| 
NIFEDIPINE$DB01115$drug$CIMETIDINE$DB00501$true$advise$drug$If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.| 
NIFEDIPINE$DB01115$drug$Mycamine$DB01141$true$advise$brand$Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. | Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. | 
NIFEDIPINE$DB01115$drug$Mycamine$DB01141$true$mechanism$brand$Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. | Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. | 
NIFEDIPINE$DB01115$drug$VARDENAFIL$DB00862$true$effect$drug$In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.| 
Nimbex$DB00565$brand$BACITRACIN A$DB00626$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nimbex$DB00565$brand$CLINDAMYCIN$DB01190$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nimbex$DB00565$brand$Colistin$DB00803$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nimbex$DB00565$brand$LINCOMYCIN$DB01627$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nimbex$DB00565$brand$LITHIUM CATION$DB01356$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nimbex$DB00565$brand$LITHIUM$DB01356$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nimbex$DB00565$brand$MAGNESIUM CATION$DB01378$true$effect$group$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nimbex$DB00565$brand$MAGNESIUM$DB01378$true$effect$group$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nimbex$DB00565$brand$PROCAINAMIDE$DB01035$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nimbex$DB00565$brand$QUINIDINE$DB00908$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nimbex$DB00565$brand$SUCCINYLCHOLINE$DB00202$true$effect$drug$Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.| The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.| 
NITROFURANTOIN$DB00698$drug$NALIDIXIC ACID$DB00779$true$effect$drug$Nitrofurantoin interferes with the therapeutic action of nalidixic acid.| 
NITROFURANTOIN$DB00698$drug$NORFLOXACIN$DB01059$true$effect$drug$The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.| 
NITROGLYCERIN$DB00727$drug$CAPTOPRIL$DB01197$true$advise$drug$therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.| 
NITROGLYCERIN$DB00727$drug$INOmax$DB00435$true$effect$brand$Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.| 
Nizoral$DB01026$brand$MIDAZOLAM$DB00683$true$mechanism$drug$Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.| 
Nizoral$DB01026$brand$TRIAZOLAM$DB00897$true$mechanism$drug$Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.| 
NOREPINEPHRINE$DB00368$drug$Bretylium tosylate$DB01158$true$effect$drug$The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.| 
NOREPINEPHRINE$DB00368$drug$SODIUM BICARBONATE$DB01390$true$int$drug$norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. | 
NORETHINDRONE$DB00717$drug$GABAPENTIN$DB00996$true$mechanism$drug$The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;| 
NORFLOXACIN$DB01059$drug$GLYBURIDE$DB01016$true$effect$drug$The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.| 
NORFLOXACIN$DB01059$drug$THEOPHYLLINE$DB00277$true$effect$drug$There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.| 
NORFLOXACIN$DB01059$drug$Tikosyn$DB00204$true$advise$brand$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
Norpace$DB00280$brand$QUINIDINE$DB00908$true$mechanism$drug$Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.| 
Nuromax$DB01135$brand$BACITRACIN A$DB00626$true$effect$group$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nuromax$DB01135$brand$CARBAMAZEPINE$DB00564$true$effect$drug$As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.| 
Nuromax$DB01135$brand$CLINDAMYCIN$DB01190$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nuromax$DB01135$brand$Colistin$DB00803$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nuromax$DB01135$brand$LINCOMYCIN$DB01627$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nuromax$DB01135$brand$LITHIUM CATION$DB01356$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nuromax$DB01135$brand$LITHIUM$DB01356$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nuromax$DB01135$brand$MAGNESIUM CATION$DB01378$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nuromax$DB01135$brand$MAGNESIUM$DB01378$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nuromax$DB01135$brand$PHENYTOIN$DB00252$true$effect$drug$As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.| 
Nuromax$DB01135$brand$PROCAINAMIDE$DB01035$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
Nuromax$DB01135$brand$QUINIDINE$DB00908$true$effect$drug$Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.| 
OUABAIN$DB01092$drug$DROPERIDOL$DB00450$true$effect$drug$Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.| 
OUABAIN$DB01092$drug$PHENTOLAMINE$DB00692$true$effect$drug$When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. | 
OXYMORPHONE$DB01192$drug$PROPOFOL$DB00818$true$effect$drug$It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. | 
Oxyphenbutazone$DB03585$drug$ASPIRIN$DB00945$true$effect$drug$Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| 
PACLITAXEL$DB01229$drug$DOXORUBICIN$DB00997$true$mechanism$drug$Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.| 
PACLITAXEL$DB01229$drug$Herceptin$DB00072$true$mechanism$brand$Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.| 
PAH$DB00345$drug$PROCAINE$DB00721$true$effect$drug$Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.| 
para-aminosalicylic acid$DB00233$drug$Vitamin B12$DB00115$true$mechanism$drug$Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| 
PARICALCITOL$DB00910$drug$ATAZANAVIR$DB01072$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$CLARITHROMYCIN$DB01211$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$INDINAVIR ANHYDROUS$DB00224$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$INDINAVIR$DB00224$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$Ketoconazole$DB01026$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$NEFAZODONE$DB01149$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$NELFINAVIR$DB05251$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$RITONAVIR$DB00503$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$SAQUINAVIR MESYLATE$DB01232$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$SAQUINAVIR$DB01232$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$TELITHROMYCIN$DB00976$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PARICALCITOL$DB00910$drug$VORICONAZOLE$DB00582$true$advise$drug$A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. | 
PAROXETINE$DB00715$drug$ARIPIPRAZOLE$DB01238$true$mechanism$drug$Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| 
PAROXETINE$DB00715$drug$ATOMOXETINE$DB00289$true$mechanism$drug$In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.| 
PAROXETINE$DB00715$drug$CLOZAPINE$DB00363$true$mechanism$drug$Paroxetine produced only minor changes in the levels of clozapine and its metabolites.| 
PAROXETINE$DB00715$drug$DULOXETINE$DB00476$true$mechanism$drug$Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.| 
PAROXETINE$DB00715$drug$SUMATRIPTAN SUCCINATE$DB00669$true$effect$drug$Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | 
PAROXETINE$DB00715$drug$SUMATRIPTAN$DB00669$true$effect$drug$Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | 
Peganone$DB00754$brand$PHENACEMIDE$DB01121$true$advise$drug$Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| 
Peganone$DB00754$brand$Phenurone$DB01121$true$advise$brand$Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| 
Pegasys$DB00008$brand$THEOPHYLLINE$DB00277$true$mechanism$drug$Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.| 
PENTAMIDINE$DB00738$drug$HIVID$DB00943$true$advise$drug$Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.| If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.| 
PENTAMIDINE$DB00738$drug$HIVID$DB00943$true$effect$drug$Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.| If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.| 
PENTAZOCINE, (-)-$DB00652$drug$Levo-Dromoran$DB00854$true$advise$brand$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| 
PENTAZOCINE, (-)-$DB00652$drug$TRIPELENNAMINE$DB00792$true$effect$drug$Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. | 
PHENARSAZINE CHLORIDE$DB00514$drug$VALDECOXIB$DB00580$true$mechanism$drug$Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.| 
PHENOBARBITAL$DB01174$drug$ACETAMINOPHEN$DB00316$true$effect$drug$Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | 
PHENOBARBITAL$DB01174$drug$ASPIRIN$DB00945$true$mechanism$brand$Phenobarbital: Decreases aspirin effectiveness by enzyme induction.| 
PHENOBARBITAL$DB01174$drug$BEXAROTENE$DB00307$true$mechanism$drug$Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| 
PHENOBARBITAL$DB01174$drug$CALCITRIOL$DB00136$true$mechanism$drug$Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| 
PHENOBARBITAL$DB01174$drug$CLONAZEPAM$DB01068$true$mechanism$drug$Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| 
PHENOBARBITAL$DB01174$drug$DICLOFENAC$DB00586$true$effect$drug$Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.| 
PHENOBARBITAL$DB01174$drug$EFAVIRENZ$DB00625$true$mechanism$drug$Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| 
PHENOBARBITAL$DB01174$drug$ETHINYL ESTRADIOL$DB00977$true$mechanism$drug$Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| 
PHENOBARBITAL$DB01174$drug$EXEMESTANE$DB00990$true$mechanism$drug$Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| 
PHENOBARBITAL$DB01174$drug$FELBAMATE$DB00949$true$mechanism$drug$Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.| 
PHENOBARBITAL$DB01174$drug$Fenoprofen$DB00573$true$mechanism$drug$Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.| 
PHENOBARBITAL$DB01174$drug$METHYLPREDNISOLONE$DB00959$true$advise$drug$Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | 
PHENOBARBITAL$DB01174$drug$METHYLPREDNISOLONE$DB00959$true$mechanism$drug$Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | 
PHENOBARBITAL$DB01174$drug$Mexitil$DB00379$true$mechanism$brand$When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | 
PHENOBARBITAL$DB01174$drug$MIFEPRISTONE$DB00834$true$mechanism$drug$John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). | 
PHENOBARBITAL$DB01174$drug$MONTELUKAST$DB00471$true$advise$drug$It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.| 
PHENOBARBITAL$DB01174$drug$Nalfon$DB00573$true$advise$brand$When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.| 
PHENOBARBITAL$DB01174$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
PHENOBARBITAL$DB01174$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
PHENOBARBITAL$DB01174$drug$Trileptal$DB00776$true$mechanism$brand$The increase of phenobarbital level, however, is small (15%) when given with Trileptal.| 
PHENYLALANINE$DB00120$drug$SELEGILINE$DB01037$true$effect$drug$Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.| 
PHENYLBUTAZONE$DB00812$drug$ASPIRIN$DB00945$true$effect$drug$Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| 
PHENYLBUTAZONE$DB00812$drug$Etodolac$DB00749$true$mechanism$drug$Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.| 
PHENYLEPHRINE$DB00388$drug$ProAmatine$DB00211$true$effect$brand$The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | 
PHENYTOIN$DB00252$drug$ALCOHOL$DB00898$true$mechanism$drug$- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine| The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| 
PHENYTOIN$DB00252$drug$AMIODARONE$DB01118$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| 
PHENYTOIN$DB00252$drug$ASPIRIN$DB00945$true$effect$brand$Phenytoin: Serum phenytoin levels may be increased by aspirin.| 
PHENYTOIN$DB00252$drug$BEXAROTENE$DB00307$true$mechanism$drug$Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| 
PHENYTOIN$DB00252$drug$BUSULFAN$DB01008$true$mechanism$drug$Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.| 
PHENYTOIN$DB00252$drug$CALCITRIOL$DB00136$true$mechanism$drug$Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| 
PHENYTOIN$DB00252$drug$Cancidas$DB00520$true$mechanism$brand$In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.| 
PHENYTOIN$DB00252$drug$CARBAMAZEPINE$DB00564$true$mechanism$drug$- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine| 
PHENYTOIN$DB00252$drug$CHLORDIAZEPOXIDE$DB00475$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| 
PHENYTOIN$DB00252$drug$CIMETIDINE$DB00501$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| 
PHENYTOIN$DB00252$drug$CIPROFLOXACIN$DB00537$true$mechanism$drug$Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.| 
PHENYTOIN$DB00252$drug$CLONAZEPAM$DB01068$true$mechanism$drug$Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| 
PHENYTOIN$DB00252$drug$CLOZAPINE$DB00363$true$mechanism$drug$Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.| 
PHENYTOIN$DB00252$drug$COUMARIN$DB04665$true$effect$group$Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| 
PHENYTOIN$DB00252$drug$COUMARIN$DB04665$true$mechanism$group$Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| 
PHENYTOIN$DB00252$drug$DEXAMETHASONE$DB01234$true$mechanism$drug$Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.| 
PHENYTOIN$DB00252$drug$DIAZEPAM$DB00829$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| 
PHENYTOIN$DB00252$drug$DICUMAROL$DB00266$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| 
PHENYTOIN$DB00252$drug$DIGITOXIN$DB01396$true$effect$drug$- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| 
PHENYTOIN$DB00252$drug$DIPHENOLIC ACID$DB00313$true$effect$drug$Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| 
PHENYTOIN$DB00252$drug$DISULFIRAM$DB00822$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| 
PHENYTOIN$DB00252$drug$DOXYCYCLINE$DB00254$true$effect$drug$Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| 
PHENYTOIN$DB00252$drug$DOXYCYCLINE$DB00254$true$mechanism$drug$Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| 
PHENYTOIN$DB00252$drug$Estrogens$DB00286$true$effect$group$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| 
PHENYTOIN$DB00252$drug$Estrogens$DB00286$true$mechanism$group$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| - Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| 
PHENYTOIN$DB00252$drug$ETHINYL ESTRADIOL$DB00977$true$mechanism$drug$Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| 
PHENYTOIN$DB00252$drug$EXEMESTANE$DB00990$true$mechanism$drug$Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| 
PHENYTOIN$DB00252$drug$FELBAMATE$DB00949$true$mechanism$drug$Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.| 
PHENYTOIN$DB00252$drug$Felbatol$DB00949$true$mechanism$brand$Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.| 
PHENYTOIN$DB00252$drug$FUROSEMIDE$DB00695$true$effect$drug$- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| 
PHENYTOIN$DB00252$drug$ISONIAZID$DB00951$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| 
PHENYTOIN$DB00252$drug$METHYLPREDNISOLONE$DB00959$true$advise$drug$Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | 
PHENYTOIN$DB00252$drug$METHYLPREDNISOLONE$DB00959$true$mechanism$drug$Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | 
PHENYTOIN$DB00252$drug$Mexitil$DB00379$true$mechanism$brand$When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | 
PHENYTOIN$DB00252$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. | 
PHENYTOIN$DB00252$drug$MIFEPRISTONE$DB00834$true$mechanism$drug$John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). | 
PHENYTOIN$DB00252$drug$Mivacron$DB01226$true$effect$brand$While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. | 
PHENYTOIN$DB00252$drug$Nimbex$DB00565$true$effect$brand$While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.| 
PHENYTOIN$DB00252$drug$Norpace$DB00280$true$mechanism$brand$If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.| 
PHENYTOIN$DB00252$drug$PHENOBARBITAL$DB01174$true$effect$drug$- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.| Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| 
PHENYTOIN$DB00252$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.| Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| 
PHENYTOIN$DB00252$drug$PHENYLBUTAZONE$DB00812$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| 
PHENYTOIN$DB00252$drug$QUETIAPINE FUMARATE$DB01224$true$mechanism$drug$This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. | 
PHENYTOIN$DB00252$drug$QUETIAPINE$DB01224$true$mechanism$drug$This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. | 
PHENYTOIN$DB00252$drug$QUINIDINE$DB00908$true$effect$drug$- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| 
PHENYTOIN$DB00252$drug$RESERPINE$DB00206$true$mechanism$drug$- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine| 
PHENYTOIN$DB00252$drug$RIFAMPIN$DB01045$true$effect$drug$- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| 
PHENYTOIN$DB00252$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
PHENYTOIN$DB00252$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
PHENYTOIN$DB00252$drug$Sular$DB00401$true$mechanism$brand$Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.| 
PHENYTOIN$DB00252$drug$SULFAPYRIDINE$DB00891$true$effect$drug$- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin| 
PHENYTOIN$DB00252$drug$THEOPHYLLINE$DB00277$true$effect$drug$- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.| With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.| 
PHENYTOIN$DB00252$drug$TOLBUTAMIDE$DB01124$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| 
PHENYTOIN$DB00252$drug$TRAZODONE$DB00656$true$mechanism$drug$The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone| 
PHENYTOIN$DB00252$drug$Trileptal$DB00776$true$mechanism$brand$1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.| 
PHENYTOIN$DB00252$drug$Valproate$DB00313$true$effect$drug$Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| 
PHENYTOIN$DB00252$drug$VALPROIC ACID$DB00313$true$effect$drug$Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable| 
Phospholine Iodide$DB01057$drug$SUCCINYLCHOLINE$DB00202$true$effect$drug$Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.| 
PHYSOSTIGMINE$DB00981$drug$ALCOHOL$DB00898$true$effect$drug$Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. | 
PIMOZIDE$DB01100$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
PIMOZIDE$DB01100$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
PIMOZIDE$DB01100$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
PIPERACILLIN ANHYDROUS$DB00319$drug$VECURONIUM$DB01339$true$effect$drug$Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.| In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.| 
PIPERACILLIN$DB00319$drug$VECURONIUM$DB01339$true$effect$drug$In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.| Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.| 
Pletal$DB01166$brand$ERYTHROMYCIN$DB00199$true$advise$drug$Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.| 
Pletal$DB01166$brand$Ketoconazole$DB01026$true$advise$drug$Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.| 
Ponstel$DB00784$brand$ASPIRIN$DB00945$true$advise$brand$Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.| 
Ponstel$DB00784$brand$FUROSEMIDE$DB00695$true$advise$drug$During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.| 
Posicor$DB01388$brand$ASTEMIZOLE$DB00637$true$mechanism$drug$Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | 
Posicor$DB01388$brand$Cisapride$DB00604$true$mechanism$drug$Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | 
Posicor$DB01388$brand$CYCLOSPORINE$DB00091$true$mechanism$drug$Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. | 
PRALIDOXIME$DB00733$drug$Atropine$DB00572$true$effect$drug$When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.| 
PRAZOSIN$DB00457$drug$ProAmatine$DB00211$true$effect$brand$ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. | 
Prinivil$DB00722$brand$AMILORIDE$DB00594$true$effect$drug$Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| 
Prinivil$DB00722$brand$LITHIUM CATION$DB01356$true$advise$drug$It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.| 
Prinivil$DB00722$brand$LITHIUM$DB01356$true$advise$drug$It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.| 
Prinivil$DB00722$brand$POTASSIUM$DB01345$true$effect$drug$Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| 
Prinivil$DB00722$brand$SPIRONOLACTONE$DB00421$true$effect$drug$Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| 
Prinivil$DB00722$brand$TRIAMTERENE$DB00384$true$effect$drug$Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| 
PROBENECID$DB01032$drug$ACETAMINOPHEN$DB00316$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$ACYCLOVIR$DB00787$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.| 
PROBENECID$DB01032$drug$ADENOSINE PHOSPHATE$DB00415$true$mechanism$drug$Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| 
PROBENECID$DB01032$drug$Alimta$DB00642$true$mechanism$brand$Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA. | 
PROBENECID$DB01032$drug$AMINOSALICYLIC ACID$DB00233$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$AMPICILLIN$DB00415$true$mechanism$drug$Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| 
PROBENECID$DB01032$drug$BUMETANIDE$DB00887$true$advise$drug$Thus, probenecid should not be administered concurrently with bumetanide.| - Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$BUMETANIDE$DB00887$true$effect$drug$Thus, probenecid should not be administered concurrently with bumetanide.| - Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$BUMETANIDE$DB00887$true$mechanism$drug$Thus, probenecid should not be administered concurrently with bumetanide.| - Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$CEFDINIR$DB00535$true$mechanism$drug$Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.| 
PROBENECID$DB01032$drug$CEFDITOREN PIVOXIL$DB01066$true$mechanism$drug$Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.| 
PROBENECID$DB01032$drug$CEFPROZIL ANHYDROUS, (E)-$DB01150$true$mechanism$drug$Concomitant administration of probenecid doubled the AUC for cefprozil.| 
PROBENECID$DB01032$drug$CIPROFLOXACIN$DB00537$true$mechanism$drug$Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.| 
PROBENECID$DB01032$drug$CLOFIBRATE$DB00636$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$CLOXACILLIN$DB01147$true$mechanism$drug$This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.| 
PROBENECID$DB01032$drug$ERTAPENEM$DB00303$true$advise$drug$When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.| Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.| 
PROBENECID$DB01032$drug$ERTAPENEM$DB00303$true$mechanism$drug$When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.| Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.| 
PROBENECID$DB01032$drug$FAMOTIDINE$DB00927$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$FUROSEMIDE$DB00695$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$MEROPENEM ANHYDROUS$DB00760$true$advise$drug$Therefore, the coadministration of probenecid with meropenem is not recommended. | Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | 
PROBENECID$DB01032$drug$MEROPENEM ANHYDROUS$DB00760$true$mechanism$drug$Therefore, the coadministration of probenecid with meropenem is not recommended. | Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | 
PROBENECID$DB01032$drug$MEROPENEM$DB00760$true$advise$drug$Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | Therefore, the coadministration of probenecid with meropenem is not recommended. | 
PROBENECID$DB01032$drug$MEROPENEM$DB00760$true$mechanism$drug$Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. | Therefore, the coadministration of probenecid with meropenem is not recommended. | 
PROBENECID$DB01032$drug$METHOTREXATE$DB00563$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$NAPROXEN$DB00788$true$mechanism$drug$Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.| 
PROBENECID$DB01032$drug$NITROFURANTOIN$DB00698$true$mechanism$drug$Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.| 
PROBENECID$DB01032$drug$NORFLOXACIN$DB01059$true$mechanism$drug$Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.| 
PROBENECID$DB01032$drug$PAH$DB00345$true$effect$drug$Probenecid depresses tubular secretion of certain weak acids such as PAH.| Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.| 
PROBENECID$DB01032$drug$PAH$DB00345$true$mechanism$drug$Probenecid depresses tubular secretion of certain weak acids such as PAH.| Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.| 
PROBENECID$DB01032$drug$PENCICLOVIR$DB00299$true$mechanism$drug$Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.| 
PROBENECID$DB01032$drug$Pipracil$DB00319$true$mechanism$brand$Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.| 
PROBENECID$DB01032$drug$RIBOFLAVIN$DB00140$true$mechanism$drug$Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin; | 
PROBENECID$DB01032$drug$THEOPHYLLINE$DB00277$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$drug$ZALCITABINE$DB00943$true$mechanism$drug$Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.| 
PROBENECID$DB01032$drug$ZIDOVUDINE$DB00495$true$mechanism$drug$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROCHLORPERAZINE$DB00433$drug$Camptosar$DB00762$true$effect$brand$The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).| 
Proleukin$DB00041$brand$DACARBAZINE$DB00851$true$effect$drug$Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.| 
Proleukin$DB00041$brand$TAMOXIFEN$DB00675$true$effect$drug$Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.| 
PROPANTHELINE$DB00782$drug$DIGOXIN$DB00390$true$mechanism$drug$Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| 
PROPOXYPHENE$DB00647$drug$ALCOHOL$DB00898$true$effect$drug$The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. | 
PROPOXYPHENE$DB00647$drug$ALPRAZOLAM$DB00404$true$mechanism$drug$Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.| 
PSEUDOEPHEDRINE$DB00852$drug$KAOLIN$DB01575$true$mechanism$drug$Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.| 
PSEUDOEPHEDRINE$DB00852$drug$ProAmatine$DB00211$true$effect$brand$The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. | 
Purinethol$DB01033$brand$Tabloid$DB00352$true$effect$brand$There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. | 
PYRIDOXINE$DB00165$drug$CISPLATIN$DB00515$true$advise$drug$however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1| 
PYRIDOXINE$DB00165$drug$Hexalen$DB00488$true$advise$brand$however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1| 
QUINIDINE$DB00908$drug$ARIPIPRAZOLE$DB01238$true$advise$drug$Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.| Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| 
QUINIDINE$DB00908$drug$ARIPIPRAZOLE$DB01238$true$mechanism$drug$Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.| Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.| 
QUINIDINE$DB00908$drug$DIGOXIN$DB00390$true$mechanism$drug$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
QUINIDINE$DB00908$drug$NIFEDIPINE$DB01115$true$mechanism$drug$Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).| 
QUINIDINE$DB00908$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
QUINIDINE$DB00908$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
QUINIDINE$DB00908$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
QUINIDINE$DB00908$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
QUININE$DB00468$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
QUININE$DB00468$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
QUININE$DB00468$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
QUININE$DB00468$drug$Tikosyn$DB00204$true$advise$brand$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
RANITIDINE$DB00863$drug$ALENDRONIC ACID$DB00630$true$mechanism$drug$Intravenous ranitidine was shown to double the bioavailability of oral alendronate.| 
RANITIDINE$DB00863$drug$CEFTIBUTEN$DB01415$true$mechanism$drug$however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.| 
RANITIDINE$DB00863$drug$Cisapride$DB00604$true$mechanism$drug$The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.| 
RANITIDINE$DB00863$drug$Iressa$DB00317$true$mechanism$brand$Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.| 
RANITIDINE$DB00863$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
Remeron$DB00370$brand$ALCOHOL$DB00898$true$effect$drug$However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. | 
Remeron$DB00370$brand$DIAZEPAM$DB00829$true$effect$drug$However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. | 
RESERPINE$DB00206$drug$Zebeta$DB00612$true$effect$brand$Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| 
RETINOL$DB00162$group$ACITRETIN$DB00459$true$advise$drug$Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.| 
Revia$DB00704$brand$DISULFIRAM$DB00822$true$effect$drug$The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.| 
RIBAVIRIN$DB00811$drug$STAVUDINE$DB00649$true$effect$drug$Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| 
RIBAVIRIN$DB00811$drug$ZIDOVUDINE$DB00495$true$effect$drug$Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| 
RIBOFLAVIN$DB00140$drug$PROBENECID$DB01032$true$effect$drug$requirements for riboflavin may be increased in patients receiving probenecid.| 
RIFABUTIN$DB00615$drug$Crixivan$DB00224$true$advise$brand$Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.| 
RIFABUTIN$DB00615$drug$EFAVIRENZ$DB00625$true$mechanism$drug$Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| 
RIFABUTIN$DB00615$drug$FLUCONAZOLE$DB00196$true$advise$drug$Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. | 
RIFABUTIN$DB00615$drug$Viracept$DB00220$true$advise$brand$It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.| Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.| 
RIFABUTIN$DB00615$drug$Viracept$DB00220$true$mechanism$brand$It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.| Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.| 
RIFAMPIN$DB01045$drug$AMPRENAVIR$DB00701$true$mechanism$drug$Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. | Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. | 
RIFAMPIN$DB01045$drug$BEXAROTENE$DB00307$true$mechanism$drug$Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| 
RIFAMPIN$DB01045$drug$Cancidas$DB00520$true$advise$brand$Patients on rifampin should receive 70 mg of CANCIDAS daily.| 
RIFAMPIN$DB01045$drug$CLOZAPINE$DB00363$true$mechanism$drug$Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.| 
RIFAMPIN$DB01045$drug$Diflucan$DB00196$true$mechanism$brand$Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. | 
RIFAMPIN$DB01045$drug$DIGOXIN$DB00390$true$mechanism$drug$Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.| 
RIFAMPIN$DB01045$drug$DILTIAZEM$DB00343$true$mechanism$drug$Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.| 
RIFAMPIN$DB01045$drug$EFAVIRENZ$DB00625$true$mechanism$drug$Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.| 
RIFAMPIN$DB01045$drug$ERLOTINIB$DB00530$true$mechanism$drug$Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.| 
RIFAMPIN$DB01045$drug$ETHINYL ESTRADIOL$DB00977$true$mechanism$drug$Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.| 
RIFAMPIN$DB01045$drug$EXEMESTANE$DB00990$true$mechanism$drug$Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.| 
RIFAMPIN$DB01045$drug$Gleevec$DB00619$true$mechanism$brand$Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).| 
RIFAMPIN$DB01045$drug$HALOPERIDOL$DB00502$true$advise$drug$Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.| 
RIFAMPIN$DB01045$drug$HALOPERIDOL$DB00502$true$mechanism$drug$Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.| 
RIFAMPIN$DB01045$drug$Ketoconazole$DB01026$true$mechanism$drug$Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.| 
RIFAMPIN$DB01045$drug$LOSARTAN$DB00678$true$mechanism$drug$Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.| 
RIFAMPIN$DB01045$drug$METHYLPREDNISOLONE$DB00959$true$advise$drug$Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | 
RIFAMPIN$DB01045$drug$METHYLPREDNISOLONE$DB00959$true$mechanism$drug$Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. | 
RIFAMPIN$DB01045$drug$Mexitil$DB00379$true$mechanism$brand$When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. | 
RIFAMPIN$DB01045$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. | 
RIFAMPIN$DB01045$drug$MONTELUKAST$DB00471$true$advise$drug$It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.| 
RIFAMPIN$DB01045$drug$NORETHINDRONE$DB00717$true$mechanism$drug$Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.| 
RIFAMPIN$DB01045$drug$Viracept$DB00220$true$mechanism$brand$Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.| 
RIFAMPIN$DB01045$drug$ZALEPLON$DB00962$true$mechanism$drug$Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.| 
RIFAMPIN$DB01045$drug$Zebeta$DB00612$true$mechanism$brand$Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.| 
RISPERIDONE$DB00734$drug$LEVODOPA$DB01235$true$effect$drug$Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.| 
Ritalin$DB00422$brand$CLOMIPRAMINE$DB01242$true$mechanism$drug$Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | 
Ritalin$DB00422$brand$DESIPRAMINE$DB01151$true$mechanism$drug$Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | 
Ritalin$DB00422$brand$GUANETHIDINE$DB01170$true$effect$drug$Ritalin may decrease the hypotensive effect of guanethidine. | 
Ritalin$DB00422$brand$IMIPRAMINE$DB00458$true$mechanism$drug$Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | 
Ritalin$DB00422$brand$PHENOBARBITAL$DB01174$true$mechanism$drug$Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | 
Ritalin$DB00422$brand$PHENYLBUTAZONE$DB00812$true$mechanism$drug$Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | 
Ritalin$DB00422$brand$PRIMIDONE$DB00794$true$mechanism$drug$Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). | 
RITONAVIR$DB00503$drug$ALMOTRIPTAN$DB00918$true$advise$drug$Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.| 
RITONAVIR$DB00503$drug$Cisapride$DB00604$true$mechanism$drug$Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
RITONAVIR$DB00503$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. | 
RITONAVIR$DB00503$drug$NEVIRAPINE$DB00238$true$advise$drug$A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.| 
RITONAVIR$DB00503$drug$Sustiva$DB00625$true$advise$brand$A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.| 
RITONAVIR$DB00503$drug$VARDENAFIL$DB00862$true$mechanism$drug$Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.| Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.| 
RITONAVIR$DB00503$drug$Viracept$DB00220$true$mechanism$brand$Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.| 
Robinul$DB00986$brand$POTASSIUM CHLORIDE$DB00761$true$mechanism$drug$Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.| 
ROPIVACAINE$DB00296$drug$FLUVOXAMINE$DB00176$true$mechanism$drug$In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. | 
ROXITHROMYCIN$DB00778$drug$ASTEMIZOLE$DB00637$true$advise$drug$Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. | 
Sanctura$DB00209$brand$DIGOXIN$DB00390$true$mechanism$drug$Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | 
Sanctura$DB00209$brand$METFORMIN$DB00331$true$mechanism$drug$Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | 
Sanctura$DB00209$brand$MORPHINE$DB00295$true$mechanism$drug$Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | 
Sanctura$DB00209$brand$PANCURONIUM$DB01337$true$mechanism$drug$Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | 
Sanctura$DB00209$brand$PROCAINAMIDE$DB01035$true$mechanism$drug$Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | 
Sanctura$DB00209$brand$TENOFOVIR$DB00300$true$mechanism$drug$Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | 
Sanctura$DB00209$brand$VANCOMYCIN$DB00512$true$mechanism$drug$Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). | 
SAQUINAVIR MESYLATE$DB01232$drug$AMPRENAVIR$DB00701$true$mechanism$drug$Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.| 
SAQUINAVIR MESYLATE$DB01232$drug$Viracept$DB00220$true$mechanism$brand$Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.| 
SAQUINAVIR$DB01232$drug$AMPRENAVIR$DB00701$true$mechanism$drug$Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.| 
SAQUINAVIR$DB01232$drug$Viracept$DB00220$true$mechanism$brand$Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.| 
SCOPOLAMINE$DB00747$drug$ALCOHOL$DB00898$true$advise$drug$Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. | 
SELEGILINE$DB01037$drug$EPHEDRINE$DB01364$true$effect$drug$One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).| 
SELEGILINE$DB01037$drug$MEPERIDINE$DB00454$true$effect$drug$The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. | 
Sensipar$DB01012$brand$ERYTHROMYCIN$DB00199$true$advise$drug$Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;| 
Sensipar$DB01012$brand$Ketoconazole$DB01026$true$advise$drug$Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;| 
SERTRALINE$DB01104$drug$SUMATRIPTAN SUCCINATE$DB00669$true$effect$drug$Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | 
SERTRALINE$DB01104$drug$SUMATRIPTAN$DB00669$true$effect$drug$Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. | 
SILDENAFIL$DB00203$drug$INDINAVIR ANHYDROUS$DB00224$true$advise$drug$Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.| 
SILDENAFIL$DB00203$drug$INDINAVIR$DB00224$true$advise$drug$Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.| 
Simulect$DB00074$brand$AZATHIOPRINE$DB00993$true$mechanism$drug$Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.| 
Simulect$DB00074$brand$MYCOPHENOLATE MOFETIL$DB00688$true$mechanism$drug$Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.| 
SIMVASTATIN$DB00641$drug$CLARITHROMYCIN$DB01211$true$effect$drug$Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.&#x0D;| 
SIROLIMUS$DB00877$drug$DILTIAZEM$DB00343$true$advise$drug$RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. | Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.| Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. | 
SIROLIMUS$DB00877$drug$DILTIAZEM$DB00343$true$mechanism$drug$RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. | Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.| Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. | 
SIROLIMUS$DB00877$drug$Mycamine$DB01141$true$advise$brand$Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. | Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. | 
SIROLIMUS$DB00877$drug$Mycamine$DB01141$true$mechanism$brand$Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. | Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. | 
SIROLIMUS$DB00877$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
Skelaxin$DB00660$brand$ALCOHOL$DB00898$true$effect$drug$SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.| 
Skelid$DB01133$brand$CALCIUM$DB01373$true$mechanism$drug$The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. | 
Skelid$DB01133$brand$INDOMETHACIN$DB00328$true$mechanism$drug$The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. | 
SODIUM SALICYLATE$DB01398$drug$TENIPOSIDE$DB00444$true$mechanism$drug$In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. | 
Sonata$DB00962$brand$ALCOHOL$DB00898$true$effect$drug$CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.| 
Sonata$DB00962$brand$CIMETIDINE$DB00501$true$mechanism$drug$Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.| 
Sonata$DB00962$brand$IMIPRAMINE$DB00458$true$effect$drug$Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.| 
SPIRONOLACTONE$DB00421$drug$DIGOXIN$DB00390$true$mechanism$drug$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
Sprycel$DB01254$brand$ATAZANAVIR$DB01072$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$CLARITHROMYCIN$DB01211$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$ERYTHROMYCIN$DB00199$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$INDINAVIR ANHYDROUS$DB00224$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$INDINAVIR$DB00224$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$Ketoconazole$DB01026$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$NEFAZODONE$DB01149$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$NELFINAVIR$DB05251$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$RITONAVIR$DB00503$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$SAQUINAVIR$DB01232$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Sprycel$DB01254$brand$TELITHROMYCIN$DB00976$true$mechanism$drug$Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.| 
Stadol NS$DB00611$brand$SUMATRIPTAN SUCCINATE$DB00669$true$effect$drug$However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| 
Stadol NS$DB00611$brand$SUMATRIPTAN SUCCINATE$DB00669$true$mechanism$drug$However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| 
Stadol NS$DB00611$brand$SUMATRIPTAN$DB00669$true$effect$drug$When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| 
Stadol NS$DB00611$brand$SUMATRIPTAN$DB00669$true$mechanism$drug$When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.| However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.| These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.| 
Starlix$DB00731$brand$TOLBUTAMIDE$DB01124$true$mechanism$drug$Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.| 
STAVUDINE$DB00649$drug$DOXORUBICIN$DB00997$true$effect$drug$In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. | 
STAVUDINE$DB00649$drug$RIBAVIRIN$DB00811$true$effect$drug$In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. | 
Strattera$DB00289$brand$Albuterol$DB01001$true$advise$drug$Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.| 
Strattera$DB00289$brand$PAROXETINE$DB00715$true$advise$drug$Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.| 
Strattera$DB00289$brand$QUINIDINE$DB00908$true$advise$drug$Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.| 
STREPTOZOCIN$DB00428$drug$DOXORUBICIN$DB00997$true$mechanism$drug$Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression; | 
STREPTOZOCIN$DB00428$drug$PHENYTOIN$DB00252$true$effect$drug$The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    | 
SUCCINYLCHOLINE$DB00202$drug$Brevibloc$DB00187$true$effect$brand$The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.| 
SUCCINYLCHOLINE$DB00202$drug$Coly-Mycin M$DB01111$true$effect$brand$Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| 
SUCCINYLCHOLINE$DB00202$drug$Mivacron$DB01226$true$advise$brand$Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. | 
SUCCINYLCHOLINE$DB00202$drug$Nimbex$DB00565$true$effect$brand$Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.| 
Sular$DB00401$brand$PHENYTOIN$DB00252$true$advise$drug$Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.| 
SULFAMETHIZOLE$DB00576$drug$TENIPOSIDE$DB00444$true$mechanism$drug$In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. | 
SULFAMETHIZOLE$DB00576$drug$TOLBUTAMIDE$DB01124$true$effect$drug$Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. | 
SULFAMETHOXAZOLE$DB01015$drug$PHENYTOIN$DB00252$true$mechanism$drug$At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate. | Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. | 
SULFAPYRIDINE$DB00891$drug$ACETAMINOPHEN$DB00316$true$int$drug$Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or| 
SULFAPYRIDINE$DB00891$drug$Tylenol$DB00316$true$int$brand$Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or| 
SULFASALAZINE$DB00795$drug$DIGOXIN$DB00390$true$mechanism$drug$Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| 
SULFASALAZINE$DB00795$drug$Enbrel$DB00005$true$effect$brand$Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.| 
SULFOXONE$DB01145$drug$TOLBUTAMIDE$DB01124$true$effect$drug$Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. | 
SUMATRIPTAN SUCCINATE$DB00669$drug$D.H.E. 45$DB00320$true$advise$brand$Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| 
SUMATRIPTAN SUCCINATE$DB00669$drug$D.H.E. 45$DB00320$true$effect$brand$Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| 
SUMATRIPTAN SUCCINATE$DB00669$drug$ESCITALOPRAM OXALATE$DB01175$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN SUCCINATE$DB00669$drug$ESCITALOPRAM$DB01175$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN SUCCINATE$DB00669$drug$FLUVOXAMINE$DB00176$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN SUCCINATE$DB00669$drug$PAROXETINE$DB00715$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN SUCCINATE$DB00669$drug$SERTRALINE$DB01104$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$drug$D.H.E. 45$DB00320$true$advise$brand$Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| 
SUMATRIPTAN$DB00669$drug$D.H.E. 45$DB00320$true$effect$brand$Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.| Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..| 
SUMATRIPTAN$DB00669$drug$ESCITALOPRAM OXALATE$DB01175$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$drug$ESCITALOPRAM$DB01175$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$drug$FLUVOXAMINE$DB00176$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$drug$PAROXETINE$DB00715$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$drug$SERTRALINE$DB01104$true$advise$drug$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUNITINIB$DB01268$drug$DOCETAXEL$DB01248$true$effect$drug$Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.| Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. | 
SUNITINIB$DB01268$drug$DOCETAXEL$DB01248$true$int$drug$Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.| Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. | 
Sustiva$DB00625$brand$CLARITHROMYCIN$DB01211$true$effect$drug$In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.| 
Sustiva$DB00625$brand$Ketoconazole$DB01026$true$mechanism$drug$SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.| 
Sustiva$DB00625$brand$RITONAVIR$DB00503$true$advise$drug$Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.| 
Sutent$DB01268$brand$ATAZANAVIR$DB01072$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$CARBAMAZEPINE$DB00564$true$mechanism$drug$Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | 
Sutent$DB01268$brand$CLARITHROMYCIN$DB01211$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$DEXAMETHASONE$DB01234$true$mechanism$drug$Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | 
Sutent$DB01268$brand$INDINAVIR ANHYDROUS$DB00224$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$INDINAVIR$DB00224$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$Ketoconazole$DB01026$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$NEFAZODONE$DB01149$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$NELFINAVIR$DB05251$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$PHENOBARBITAL$DB01174$true$mechanism$drug$Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | 
Sutent$DB01268$brand$PHENYTOIN$DB00252$true$mechanism$drug$Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | 
Sutent$DB01268$brand$RIFABUTIN$DB00615$true$mechanism$drug$Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | 
Sutent$DB01268$brand$RIFAMPIN$DB01045$true$mechanism$drug$Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. | 
Sutent$DB01268$brand$RITONAVIR$DB00503$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$SAQUINAVIR$DB01232$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Sutent$DB01268$brand$TELITHROMYCIN$DB00976$true$mechanism$drug$Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. | 
Symlin$DB01278$brand$Atropine$DB00572$true$advise$drug$Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). | 
TACROLIMUS ANHYDROUS$DB00864$drug$BOSENTAN ANHYDROUS$DB00559$true$advise$drug$Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| 
TACROLIMUS ANHYDROUS$DB00864$drug$BOSENTAN ANHYDROUS$DB00559$true$mechanism$drug$Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| 
TACROLIMUS ANHYDROUS$DB00864$drug$BOSENTAN$DB00559$true$advise$drug$Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| 
TACROLIMUS ANHYDROUS$DB00864$drug$BOSENTAN$DB00559$true$mechanism$drug$Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| 
TACROLIMUS ANHYDROUS$DB00864$drug$FLUCONAZOLE$DB00196$true$advise$drug$Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored. | 
TACROLIMUS ANHYDROUS$DB00864$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
TACROLIMUS ANHYDROUS$DB00864$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
TACROLIMUS ANHYDROUS$DB00864$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
TACROLIMUS$DB00864$drug$BOSENTAN ANHYDROUS$DB00559$true$advise$drug$Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| Caution should be exercised if tacrolimus and bosentan are used together.| 
TACROLIMUS$DB00864$drug$BOSENTAN ANHYDROUS$DB00559$true$mechanism$drug$Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| Caution should be exercised if tacrolimus and bosentan are used together.| 
TACROLIMUS$DB00864$drug$BOSENTAN$DB00559$true$advise$drug$Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| 
TACROLIMUS$DB00864$drug$BOSENTAN$DB00559$true$mechanism$drug$Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| 
TACROLIMUS$DB00864$drug$FLUCONAZOLE$DB00196$true$advise$drug$Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored. | 
TACROLIMUS$DB00864$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
TACROLIMUS$DB00864$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
TACROLIMUS$DB00864$drug$Sprycel$DB01254$true$advise$brand$Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.| 
TADALAFIL$DB00820$drug$INDINAVIR ANHYDROUS$DB00224$true$advise$drug$Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.| 
TADALAFIL$DB00820$drug$INDINAVIR$DB00224$true$advise$drug$Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.| 
Tagamet$DB00501$brand$CHLORDIAZEPOXIDE$DB00475$true$mechanism$drug$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$brand$DIAZEPAM$DB00829$true$mechanism$drug$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$brand$LIDOCAINE$DB05291$true$mechanism$drug$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$brand$METRONIDAZOLE$DB00916$true$mechanism$drug$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$brand$NIFEDIPINE$DB01115$true$mechanism$drug$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$brand$PHENYTOIN$DB00252$true$mechanism$drug$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$brand$Theo-Dur$DB00277$true$mechanism$brand$However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.| 
Tagamet$DB00501$brand$THEOPHYLLINE$DB00277$true$mechanism$drug$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.| 
Tambocor$DB01195$brand$DIGOXIN$DB00390$true$mechanism$drug$During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.| 
TAMOXIFEN$DB00675$drug$ANASTROZOLE$DB01217$true$advise$drug$Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).| 
TAMOXIFEN$DB00675$drug$PAROXETINE$DB00715$true$advise$drug$It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. | 
Tarceva$DB00530$brand$ATAZANAVIR$DB01072$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$CLARITHROMYCIN$DB01211$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$INDINAVIR ANHYDROUS$DB00224$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$INDINAVIR$DB00224$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$Ketoconazole$DB01026$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$NEFAZODONE$DB01149$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$NELFINAVIR$DB05251$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$RIFAMPIN$DB01045$true$advise$drug$If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.| 
Tarceva$DB00530$brand$RITONAVIR$DB00503$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$SAQUINAVIR MESYLATE$DB01232$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$SAQUINAVIR$DB01232$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$Tao$DB01361$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$TELITHROMYCIN$DB00976$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$TROLEANDOMYCIN$DB01361$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Tarceva$DB00530$brand$VORICONAZOLE$DB00582$true$advise$drug$Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .| 
Targretin$DB00307$brand$GEMFIBROZIL$DB01241$true$mechanism$drug$Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| 
Taxol$DB01229$brand$CISPLATIN$DB00515$true$effect$drug$In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).| Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.| 
Taxol$DB01229$brand$CISPLATIN$DB00515$true$mechanism$drug$In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).| Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.| 
TENIPOSIDE$DB00444$drug$Taxol$DB01229$true$advise$brand$Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.| 
TERBINAFINE$DB00857$drug$CAFFEINE$DB00201$true$mechanism$drug$Terbinafine decreases the clearance of caffeine by 19%. | 
TERBINAFINE$DB00857$drug$CIMETIDINE$DB00501$true$mechanism$drug$Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. | 
TERBINAFINE$DB00857$drug$CYCLOSPORINE$DB00091$true$mechanism$drug$Terbinafine increases the clearance of cyclosporine by 15%. | 
TERBINAFINE$DB00857$drug$RIFAMPIN$DB01045$true$mechanism$drug$Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. | 
TETRACYCLINE$DB00759$drug$BISMUTH SUBSALICYLATE$DB01294$true$mechanism$drug$Absorption of tetracycline is impaired by bismuth subsalicylate.| 
TETRACYCLINE$DB00759$drug$DIGOXIN$DB00390$true$mechanism$drug$Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| 
TETRACYCLINE$DB00759$drug$METHOXYFLURANE$DB01028$true$effect$drug$The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.| The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. | 
TETRACYCLINE$DB00759$drug$Penthrane$DB01028$true$effect$brand$The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.| 
TETRACYCLINE$DB00759$group$METHOXYFLURANE$DB01028$true$effect$drug$The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.| The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. | 
THEOPHYLLINE$DB00277$drug$ACETAMINOPHEN$DB00316$true$mechanism$drug$Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; | 
THEOPHYLLINE$DB00277$drug$ENOXACIN$DB00467$true$effect$drug$Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.| 
THEOPHYLLINE$DB00277$drug$ERYTHROMYCIN$DB00199$true$advise$drug$In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.| 
THEOPHYLLINE$DB00277$drug$Lansoprazole$DB00448$true$advise$drug$Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.| 
THEOPHYLLINE$DB00277$drug$Mexitil$DB00379$true$mechanism$brand$This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. | 
THEOPHYLLINE$DB00277$drug$Pegasys$DB00008$true$advise$brand$Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.| 
THEOPHYLLINE$DB00277$drug$PHENYTOIN$DB00252$true$mechanism$drug$Enhanced theophylline clearance secondary to phenytoin therapy.&#x0D;| This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration. | 
THIABENDAZOLE$DB00730$drug$THEOPHYLLINE$DB00277$true$mechanism$drug$Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. | 
THIAMINE ION$DB00152$drug$STAVUDINE$DB00649$true$int$drug$Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants| 
THIAMINE$DB00152$drug$STAVUDINE$DB00649$true$int$drug$Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants| 
TIAGABINE$DB00906$drug$CARBAMAZEPINE$DB00564$true$mechanism$drug$Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.| 
TIAGABINE$DB00906$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| 
TIAGABINE$DB00906$drug$PHENYTOIN$DB00252$true$mechanism$drug$Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.| 
TIAGABINE$DB00906$drug$PRIMIDONE$DB00794$true$mechanism$drug$Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| 
TIAGABINE$DB00906$drug$Valproate$DB00313$true$mechanism$drug$Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.| 
TICAGRELOR$DB08816$drug$ASPIRIN$DB00945$true$effect$brand$The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). | 
Tikosyn$DB00204$brand$CIMETIDINE$DB00501$true$advise$drug$If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.| 
Tikosyn$DB00204$brand$Verapamil$DB00661$true$mechanism$drug$Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.| 
TIMOLOL$DB00373$drug$GUANFACINE$DB01018$true$effect$drug$Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.| 
Tobi$DB00684$brand$ETHACRYNIC ACID$DB00903$true$advise$drug$TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| 
Tobi$DB00684$brand$FUROSEMIDE$DB00695$true$advise$drug$TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| 
Tobi$DB00684$brand$MANNITOL$DB00742$true$advise$drug$TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| 
Tobi$DB00684$brand$Pulmozyme$DB00003$true$effect$brand$In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. | 
Tobi$DB00684$brand$UREA$DB03904$true$advise$drug$TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.| 
TOLBUTAMIDE$DB01124$drug$APREPITANT$DB00673$true$mechanism$drug$Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.| 
TOLBUTAMIDE$DB01124$drug$Atromid-S$DB00636$true$effect$brand$The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.| 
TOLBUTAMIDE$DB01124$drug$TENIPOSIDE$DB00444$true$mechanism$drug$In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. | 
Tolectin$DB00500$brand$METHOTREXATE$DB00563$true$advise$drug$TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. | Caution should be used if TOLECTIN is administered concomitantly with methotrexate. | 
Tolectin$DB00500$brand$METHOTREXATE$DB00563$true$mechanism$drug$TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. | Caution should be used if TOLECTIN is administered concomitantly with methotrexate. | 
TOPIRAMATE$DB00273$drug$ETHINYL ESTRADIOL$DB00977$true$mechanism$drug$Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.| 
Toradol$DB00465$brand$ALPRAZOLAM$DB00404$true$effect$drug$Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).| 
Toradol$DB00465$brand$CARBAMAZEPINE$DB00564$true$effect$drug$Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).| 
Toradol$DB00465$brand$FUROSEMIDE$DB00695$true$effect$drug$Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).| 
Toradol$DB00465$brand$PHENYTOIN$DB00252$true$effect$drug$Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).| 
Toradol$DB00465$brand$PROBENECID$DB01032$true$advise$drug$Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.| Therefore, concomitant use of TORADOL and probenecid is contraindicated.| 
Toradol$DB00465$brand$PROBENECID$DB01032$true$mechanism$drug$Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.| Therefore, concomitant use of TORADOL and probenecid is contraindicated.| 
Toradol$DB00465$brand$THIOTHIXENE$DB01623$true$effect$drug$Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).| 
Tracleer$DB00559$brand$GLYBURIDE$DB01016$true$advise$drug$Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.| 
Trecator$DB00609$brand$ISONIAZID$DB00951$true$mechanism$drug$Trecator has been found to temporarily raise serum concentrations of isoniazid.| 
Trental$DB00806$brand$THEOPHYLLINE$DB00277$true$mechanism$drug$Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. | 
Triacetyloleandomycin$DB01361$drug$ERGOTAMINE$DB00696$true$mechanism$drug$The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| 
TRIAMTERENE$DB00384$drug$DOFETILIDE$DB00204$true$advise$drug$In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| 
TRIAMTERENE$DB00384$drug$Indocin$DB00328$true$effect$brand$It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.| 
TRIAMTERENE$DB00384$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
TRIAZOLAM$DB00897$drug$APREPITANT$DB00673$true$advise$drug$The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| 
TRIAZOLAM$DB00897$drug$DILTIAZEM$DB00343$true$mechanism$drug$The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.| 
TRIAZOLAM$DB00897$drug$FLUVOXAMINE$DB00176$true$mechanism$drug$Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| 
TRIAZOLAM$DB00897$drug$SAQUINAVIR MESYLATE$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
TRIAZOLAM$DB00897$drug$SAQUINAVIR$DB01232$true$mechanism$drug$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
TRIAZOLAM$DB00897$drug$TIAGABINE$DB00906$true$advise$drug$Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.| 
Trileptal$DB00776$brand$Felodipine$DB01023$true$mechanism$drug$Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].| 
Trileptal$DB00776$brand$PHENYTOIN$DB00252$true$advise$drug$Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.| 
TRILOSTANE$DB01108$drug$Mitotane$DB00648$true$int$drug$Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).| 
TRIMETHOPRIM$DB00440$drug$PHENYTOIN$DB00252$true$mechanism$drug$Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. | Trimethoprim may inhibit the hepatic metabolism of phenytoin. | 
TRIMETREXATE$DB01157$drug$ERYTHROMYCIN$DB00199$true$effect$drug$Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | 
TRIMETREXATE$DB01157$drug$FLUCONAZOLE$DB00196$true$effect$drug$Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | 
TRIMETREXATE$DB01157$drug$Ketoconazole$DB01026$true$effect$drug$Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | 
TRIMETREXATE$DB01157$drug$RIFABUTIN$DB00615$true$effect$drug$Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | 
TRIMETREXATE$DB01157$drug$RIFAMPIN$DB01045$true$effect$drug$Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. | 
TRIPELENNAMINE$DB00792$drug$PENTAZOCINE, (-)-$DB00652$true$effect$drug$Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. | 
TRIPROLIDINE$DB00427$drug$ALCOHOL$DB00898$true$effect$drug$Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. | 
Trisenox$DB01169$brand$AMPHOTERICIN B$DB00681$true$advise$drug$Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).| 
TROLEANDOMYCIN$DB01361$drug$Cisapride$DB00604$true$mechanism$drug$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
TROLEANDOMYCIN$DB01361$drug$METHYLPREDNISOLONE$DB00959$true$mechanism$drug$Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. | 
TROVAFLOXACIN$DB00685$drug$MORPHINE$DB00295$true$mechanism$drug$Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. | 
TUBOCURARINE$DB01199$drug$Coly-Mycin M$DB01111$true$effect$brand$Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.| 
VALDECOXIB$DB00580$drug$DEXTROMETHORPHAN$DB00514$true$mechanism$drug$Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| 
VALDECOXIB$DB00580$drug$DIAZEPAM$DB00829$true$effect$drug$Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.| 
VALDECOXIB$DB00580$drug$FLUCONAZOLE$DB00196$true$mechanism$drug$Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.| Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| 
VALDECOXIB$DB00580$drug$GLYBURIDE$DB01016$true$mechanism$drug$Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.| 
VALDECOXIB$DB00580$drug$Ketoconazole$DB01026$true$mechanism$drug$Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.| Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| 
VALDECOXIB$DB00580$drug$LITHIUM CATION$DB01356$true$mechanism$drug$Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.| 
VALDECOXIB$DB00580$drug$LITHIUM$DB01356$true$mechanism$drug$Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.| 
VALDECOXIB$DB00580$drug$PHENARSAZINE CHLORIDE$DB00514$true$mechanism$drug$Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| 
VALDECOXIB$DB00580$drug$PHENYTOIN$DB00252$true$advise$drug$Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.| Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).| 
VALDECOXIB$DB00580$drug$PHENYTOIN$DB00252$true$mechanism$drug$Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.| Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).| 
Valproate$DB00313$drug$ISONIAZID$DB00951$true$mechanism$drug$Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.| 
Valproate$DB00313$drug$TIAGABINE$DB00906$true$mechanism$drug$Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.| 
VALPROIC ACID$DB00313$drug$PHENOBARBITAL$DB01174$true$effect$drug$Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | 
VALPROIC ACID$DB00313$drug$PHENOBARBITAL$DB01174$true$mechanism$drug$Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. | Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. | 
VALPROIC ACID$DB00313$drug$TEMOZOLOMIDE$DB00853$true$mechanism$drug$Administration of valproic acid decreases oral clearance of temozolomide by about 5%. | 
VARDENAFIL$DB00862$drug$ERYTHROMYCIN$DB00199$true$advise$drug$It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.| 
VARDENAFIL$DB00862$drug$INDINAVIR ANHYDROUS$DB00224$true$advise$drug$It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.| Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.| Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.| 
VARDENAFIL$DB00862$drug$INDINAVIR ANHYDROUS$DB00224$true$mechanism$drug$It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.| Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.| Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.| 
VARDENAFIL$DB00862$drug$INDINAVIR$DB00224$true$advise$drug$It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.| Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.| Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.| 
VARDENAFIL$DB00862$drug$INDINAVIR$DB00224$true$mechanism$drug$It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.| Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.| Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.| 
VARDENAFIL$DB00862$drug$Ketoconazole$DB01026$true$advise$drug$A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.| Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.| 
VARDENAFIL$DB00862$drug$RITONAVIR$DB00503$true$advise$drug$The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.| Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.| Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.| 
VARDENAFIL$DB00862$drug$RITONAVIR$DB00503$true$mechanism$drug$The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.| Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.| Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.| 
VARDENAFIL$DB00862$drug$TAMSULOSIN$DB00706$true$effect$drug$In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.| Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.| 
Verapamil$DB00661$drug$Adenocard$DB00640$true$effect$brand$Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| 
Verapamil$DB00661$drug$DIGOXIN$DB00390$true$mechanism$drug$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
Verapamil$DB00661$drug$DOFETILIDE$DB00204$true$effect$drug$In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.| 
Verapamil$DB00661$drug$MIDAZOLAM$DB00683$true$mechanism$drug$Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. | 
Verapamil$DB00661$drug$PRAMIPEXOLE$DB00413$true$mechanism$drug$Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. | 
Verapamil$DB00661$drug$Tambocor$DB01195$true$advise$brand$Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.| 
Vesicare$DB01591$brand$Ketoconazole$DB01026$true$advise$drug$Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. | 
Videx$DB00900$brand$CIPROFLOXACIN$DB00537$true$advise$drug$Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| 
Videx$DB00900$brand$Factive$DB01155$true$advise$brand$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| 
Videx$DB00900$brand$GANCICLOVIR$DB01004$true$mechanism$drug$Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).| A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).| 
Videx$DB00900$brand$NORFLOXACIN$DB01059$true$advise$drug$Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| 
Vigabatrin$DB01080$drug$CARBAMAZEPINE$DB00564$true$mechanism$drug$A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine. | 
Vigabatrin$DB01080$drug$PHENYTOIN$DB00252$true$mechanism$drug$In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. | 
VINDESINE$DB00309$drug$PHENYTOIN$DB00252$true$int$drug$Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine| 
Vioxx$DB00533$brand$BENAZEPRIL$DB00542$true$effect$drug$In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.| 
Vioxx$DB00533$brand$LITHIUM CATION$DB01356$true$advise$drug$Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.| 
Vioxx$DB00533$brand$LITHIUM$DB01356$true$advise$drug$Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.| 
Vioxx$DB00533$brand$METHOTREXATE$DB00563$true$advise$drug$Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.| At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.| 
Vioxx$DB00533$brand$METHOTREXATE$DB00563$true$mechanism$drug$Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.| At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.| 
Vioxx$DB00533$brand$RIFAMPIN$DB01045$true$mechanism$drug$Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.| 
Vioxx$DB00533$brand$THEOPHYLLINE$DB00277$true$advise$drug$Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.| Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.| 
Vioxx$DB00533$brand$THEOPHYLLINE$DB00277$true$mechanism$drug$Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.| Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.| 
Viracept$DB00220$brand$AMIODARONE$DB01118$true$advise$drug$Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| 
Viracept$DB00220$brand$ASTEMIZOLE$DB00637$true$advise$drug$Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.| 
Viracept$DB00220$brand$Cisapride$DB00604$true$advise$drug$Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| 
Viracept$DB00220$brand$MIDAZOLAM$DB00683$true$advise$drug$Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| 
Viracept$DB00220$brand$QUINIDINE$DB00908$true$advise$drug$Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| 
Viracept$DB00220$brand$RIFABUTIN$DB00615$true$advise$drug$Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin| 
Viracept$DB00220$brand$RIFAMPIN$DB01045$true$advise$drug$VIRACEPT and rifampin should not be coadministered.| Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| 
Viracept$DB00220$brand$TRIAZOLAM$DB00897$true$advise$drug$Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride| 
Vistide$DB00369$brand$AMIKACIN$DB00479$true$advise$drug$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$brand$AMPHOTERICIN B$DB00681$true$advise$drug$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$brand$FOSCARNET$DB00529$true$advise$drug$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$brand$PENTAMIDINE$DB00738$true$advise$drug$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$brand$TOBRAMYCIN$DB00684$true$advise$drug$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$brand$VANCOMYCIN$DB00512$true$advise$drug$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vitamin B1$DB00152$drug$STAVUDINE$DB00649$true$int$drug$Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants| 
Vitamin B12$DB00115$drug$AMINOSALICYLIC ACID$DB00233$true$advise$drug$Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.| 
Vitamin B12$DB00115$drug$FOLIC ACID$DB00158$true$int$drug$Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.| 
Welchol$DB00930$brand$Calan SR$DB00661$true$mechanism$brand$WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.| 
Welchol$DB00930$brand$Verapamil$DB00661$true$mechanism$drug$WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.| 
Wellbutrin$DB01156$brand$AMANTADINE$DB00915$true$advise$drug$Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.| 
Wellbutrin$DB01156$brand$Cyclophosphamide$DB00531$true$int$drug$Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).| 
Wellbutrin$DB01156$brand$LEVODOPA$DB01235$true$advise$drug$Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.| 
Wellbutrin$DB01156$brand$THEOPHYLLINE$DB00277$true$advise$drug$Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.| 
Xenical$DB01083$brand$CYCLOSPORINE$DB00091$true$mechanism$drug$Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. | 
ZAFIRLUKAST$DB00549$drug$Tikosyn$DB00204$true$advise$brand$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
ZALCITABINE$DB00943$drug$ALUMINUM$DB01370$true$advise$drug$The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.| 
ZALCITABINE$DB00943$drug$LAMIVUDINE$DB00709$true$advise$drug$Concomitant use of zalcitabine and lamivudine is not recommended.| Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);| These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.| 
ZALCITABINE$DB00943$drug$LAMIVUDINE$DB00709$true$effect$drug$Concomitant use of zalcitabine and lamivudine is not recommended.| Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);| These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.| 
ZALCITABINE$DB00943$drug$MAGNESIUM CATION$DB01378$true$advise$drug$The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.| 
ZALCITABINE$DB00943$drug$MAGNESIUM$DB01378$true$advise$drug$The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.| 
ZALCITABINE$DB00943$drug$METOCLOPRAMIDE$DB01233$true$mechanism$drug$Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.| 
ZALCITABINE$DB00943$drug$ZDV$DB00495$true$effect$drug$Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).| 
ZALEPLON$DB00962$drug$ERYTHROMYCIN$DB00199$true$mechanism$drug$Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.| 
Zavesca$DB00419$brand$Cerezyme$DB00053$true$mechanism$brand$While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. | 
Zebeta$DB00612$brand$CLONIDINE$DB00575$true$advise$drug$In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.| 
Zebeta$DB00612$brand$DILTIAZEM$DB00343$true$advise$drug$ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.| 
Zebeta$DB00612$brand$Verapamil$DB00661$true$advise$drug$ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.| 
Zemplar$DB00910$brand$Ketoconazole$DB01026$true$advise$drug$Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. | 
Zemuron$DB00728$brand$SUCCINYLCHOLINE$DB00202$true$advise$drug$If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. | 
ZIDOVUDINE$DB00495$drug$PROBENECID$DB01032$true$advise$drug$Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.| 
ZIDOVUDINE$DB00495$drug$STAVUDINE$DB00649$true$effect$drug$Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. | 
ZIDOVUDINE$DB00495$drug$Viracept$DB00220$true$advise$brand$A dose adjustment is not needed when zidovudine is administered with VIRACEPT.| 
ZIDOVUDINE$DB00495$drug$Zerit$DB00649$true$advise$brand$Therefore, use of zidovudine in combination with ZERIT should be avoided. | 
ZINC$DB01593$drug$Factive$DB01155$true$advise$brand$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| 
ZINC$DB01593$drug$NORFLOXACIN$DB01059$true$advise$drug$Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| 
Zolinza$DB02546$brand$DIPHENOLIC ACID$DB00313$true$effect$drug$Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). | 
Zolinza$DB02546$brand$VALPROIC ACID$DB00313$true$effect$drug$Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). | 
Zopiclone$DB01198$drug$RIFAMPIN$DB01045$true$mechanism$drug$Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.| 
Zopiclone$DB01198$drug$Romazicon$DB01205$true$effect$brand$The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.| 
